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AUROC: Area under receiver operating characteristic curves 
ASPRE: Combined multi-marker screening and randomised patient treatment with 
ASPirin for evidence-based PREeclampsia  
ACOG: American Congress of Obstetricians and Gynaecologists 
ART: assisted reproductive techniques 
-hCG: Human chorionic gonadotropin 
BMI: Body mass index 
BP: Blood pressure 
cfDNA: cell free deoxyribonucleic acid 
CH: Chronic hypertension 
CI: Confidence interval 
CRL: Crown-rump length 
CUSUM: Cumulative sum 
DELFIA: Dissociation-Enhanced Lanthanide Fluorescent Immunoassay 
DR: Detection rate 
FPR: False positive rate 
GA: gestational age 
GH: Gestational hypertension 
HLA: Human leukocyte antigens 
HELLP haemolytic anaemia, elevated liver enzymes, low platelet count 
ISSHP: International Society for Study of Hypertension in Pregnancy 
IQR: Inter quartile range 
IVF: In-vitro fertilisation 
LDL: low-density lipoproteins 
LMWH: Low molecular weight heparin 
MAP: Mean arterial pressure 
MBRRACE-UK: Mothers and Babies: Reducing Risk through Audits and Confidential 
Enquiries across the UK 
MoM: Multiple of median 
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NK: Natural killer 
NT: Nuchal translucency 
NICE: National Institute of Health and Clinical Excellence 
OR: Odds ratio 
PAPP-A: Pregnancy associated plasma protein-A 
PE: Preeclampsia 
PI: Pulsatility index 
PlGF: Placental growth factor 
PRECOG: Preeclampsia Community Guideline 
RCT: Randomized controlled trial 
RR: Relative risk 
SD: Standard deviation 
sEng: Soluble Endoglin 
sFlt-1: Soluble fms-like tyrosine kinase-1 
SNP: Single-nucleotide polymorphisms  
TGF-b1: transforming growth factor-β1 
TV: transvaginal 
UK: United Kingdom 
VEGF: Vascular endothelial growth factor 





Preeclampsia affects 2-3% of all pregnancies and is a major cause of maternal and perinatal 
morbidity and mortality. In the last ten years, extensive research has been devoted to 
screening for preeclampsia with the aim of reducing the prevalence of the disease through 
pharmacologic intervention in the high-risk group and to minimize perinatal morbidity and 
mortality by tailoring antenatal care accordingly to determine the appropriate time and place 
for delivery. 
The purpose of this study was to develop a first trimester screening model for preeclampsia 
combining a variety of elements from the maternal demographic characteristics and medical 
history with biophysical and biochemical markers. This model was subsequently prospectively 
validated on a new dataset. The efficacy of the developed screening model was then compared 
to the first trimester approaches to screening recommended by the National Institute for Health 
and Care Excellence and the American College of Obstetricians and Gynecologists.   
The material covered in this thesis was published in three papers in peer reviewed journals. 
The first publication involved using data from 35,948 singleton pregnancies that included 1,058 
preeclamptic pregnancies (2.9%). Bayes theorem was used to combine the a priori risk from 
maternal factors with various combinations of uterine artery pulsatility index, mean arterial 
pressure, serum pregnancy-associated plasma protein-A, and placental growth factor multiple 
of the median values. Five-fold cross validation was used to assess the performance of 
screening for preeclampsia in pregnant women that delivered at <37 weeks’ gestation and ≥37 
weeks’ gestation by models that combined maternal factors with individual biomarkers and 
their combination with screening by maternal factors alone 
In pregnancies that experienced preeclampsia, the values of uterine artery PI and mean arterial 
pressure were increased, and the values of serum pregnancy-associated plasma protein-A 
and placental growth factor were decreased. For all biomarkers, the deviation from normal was 
greater for early than late preeclampsia; therefore, the performance of screening was related 
inversely to the gestational age at which delivery became necessary for maternal and/or fetal 
indications. Combined screening by maternal factors, uterine artery PI, mean arterial pressure, 
and placental growth factor predicted 75%, of preeclampsia <37 weeks and 47% preeclampsia 
≥37 weeks’ gestation, at a false positive rate of 10%. 
The second study examined the diagnostic accuracy of the above model in a prospective first-
trimester multicentre study of screening for preeclampsia in 8775 singleton pregnancies. The 
detection rates (DRs) and false-positive rates (FPRs) for delivery with preeclampsia <32, <37 
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and ≥37 weeks’ gestation were estimated and compared with those for the dataset used for 
development of the algorithm. In this study population, 239 (2.7%) cases developed PE, of 
which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed preeclampsia <32, <37 and ≥37 weeks’ 
gestation, respectively. With combined screening using the above model, the DR was 100% 
for preeclampsia <32 weeks, 75% for preeclampsia <37 weeks and 43% for PE ≥37 weeks, at 
a 10% FPR. These DRs were similar to the estimated rates for the dataset used for 
development of the model: 89% for preeclampsia <32 weeks, 75% for PE <37 weeks and 47% 
for PE ≥37 weeks. 
The third component of this thesis was to compare the performance of screening for 
preeclampsia based on risk factors from the medical history, as recommended by NICE and 
ACOG, with our model developed in the first study. Screening with use of NICE guidelines 
detected 41% of preeclampsia at <32 weeks, 39% of PE at <37 weeks and 34% of PE at ≥37 
weeks, at 10.2% FPR. Screening with use of ACOG recommendations detected 94% of PE at 
<32 weeks, 90% of PE at <37 weeks and 89% ≥37 weeks, at 64.2% FPR. Screening based 
on the ACOG recommendations for use of aspirin only detected 6% of PE at <32 weeks, 5% 
of PE at <37 weeks and 2% of PE at ≥37 weeks, at a 0.2% FPR. 
The findings of these studies demonstrate that a combination of maternal factors, biophysical 
and biochemical markers can effectively identify women at high-risk of developing early 
preeclampsia and that the model developed in this study performs better than the screening 
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AIMS OF THE THESIS 
 
• To describe the background of preeclampsia, its pathogenesis, the various approaches 
to first trimester screening for preeclampsia, and potential pharmacological treatment 
of the disorder. 
 
• To investigate the performance of screening for preeclampsia based on a survival time 
model which treats gestation at delivery as a continuous variable and using Bayes 
theorem to combine information from maternal characteristics and biomarker MoM 
values. 
 
• To prospectively examine, in a European multicentre study, the diagnostic accuracy of 
the above model for prediction of preeclampsia by a combination of maternal factors 
and biomarkers at 11-13 weeks’ gestation. 
 
• To compare the accuracy of this first-trimester screening model for preeclampsia with 
that of the models proposed by the American college of Obstetricians and 






CHAPTER 1 INTRODUCTION 
  
1.1 Background 
In 1739, Francois Boissier de Sauvages de Lacroix, a French physician described and 
contrasted an acute form of convulsion with what is now known as epilepsy (Chesley, 1974). 
He described several species of the genus eclampsia, one of which was eclampsia 
parturientum. It was not until 1840 when proteinuria, in the context of eclamptic seizures, was 
described and hypertension, recorded by sphygmographic tracings, followed shortly after. The 
term preeclampsia (PE) was coined in 1894 when it was reported that high blood pressure and 
proteinuria could occur in pregnant women, without eclamptic seizures (Chesley, 1984). 
PE is a multisystem disorder of pregnancy classically characterised with the onset of 
hypertension after 20 weeks’ gestation in the presence of proteinuria. PE typically affects 2-
3% of pregnant women (World Health Organisation, 2005; Confidential Enquiry into Maternal 
and Child Health, 2008; Duley, 2009; Cantwell et al., 2011) and it is one of the leading causes 
of maternal mortality, with an estimated 75,000 maternal deaths worldwide attributed to 
hypertensive disorders in pregnancy (Khan et al., 2006). Severe early PE, requiring delivery 
<34 weeks’ gestation, occurs in 0.3-0.5% of pregnancies making it the most common cause of 
iatrogenic prematurity and with this brings the associated significant perinatal morbidity and 
mortality (Witlin et al., 2000; Irgens et al., 2001; von Dadelszen et al., 2003; Papageorghiou, 
2008). 
PE is a disorder with a wide spectrum. This can range from developing mildly raised blood 
pressure with proteinuria at term, requiring no further action other than enhanced surveillance 
and timely induction of labour, to being delivered prematurely due to a fulminating form of the 
disease potentially leading to multi organ failure and seizures with a peri-viable fetus. 
The classic triad of symptoms comprise of headache, visual disturbance and epigastric pain. 
These are the clinical manifestations of abnormal cerebral perfusion, retinal arteriolar spasm 
or oedema and hepatic capsular distension, respectively. They are the commonest symptoms 
that precede an eclamptic seizure. The presence of these symptoms, are not necessarily a 
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WHO - World Health Organization 
NICE - National Institute of Health and Clinical Excellence 
ACOG – American College of Obstetricians and Gynecologists 
ISSHP - International Society for the Study of Hypertension in Pregnancy 
1.2 Definition of Preeclampsia 
PE is broadly defined as development of hypertension and proteinuria in a previously 
normotensive woman. There are, however, differing opinions as to what the exact diagnostic 
criteria for the disorder are or should be.  
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There are several definitions for diagnosis of PE which have been reported in published 
literature and proposed by various professional bodies Consequently, this has resulted in a 
number of different guidelines produced by professional bodies worldwide for the diagnosis 
and management of PE WHO, 2005; NICE, 2010; ACOG, 2013; Tranquilli et al., 2014). A 
summary of various definitions proposed is shown in Table 1.1. The accepted definition of PE 
is however, that of the International Society for the Study of Hypertension in Pregnancy 
(ISSHP) (Davey and MacGillivray, 1988; Brown et al., 2001, Tranquilli et al., 2014). 
1.2.1 ISSHP Diagnostic criteria 
Whether or not to include proteinuria as an essential part of the diagnosis of PE was one of 
the major reasons for the lack of consensus and controversy regarding diagnosis. This was 
recognised by the ISSHP and they subsequently recommended that a broad definition, at times 
not including proteinuria, could be applied for the clinical definition of PE. Stating also that the 
inclusion of proteinuria, would ensure more specificity around the diagnosis when reporting 
clinical criteria for patients enrolled in scientific research (Tranquilli et al., 2014). 
For the purposes of this research, the ISSHP classification of hypertensive disorders of 
pregnancy was chosen as it represents a consensus view of an appropriate definition for 





Table 1.2 The revised ISSHP classification (2013) for hypertensive disorders in pregnancy 
(Tranquili et al., 2014). 
________________________________________________________________ 
The revised ISSHP classification (2013) for hypertensive disorders in pregnancy 
________________________________________________________________ 
• Chronic hypertension 
• Gestational hypertension 
• Preeclampsia – de novo or superimposed on chronic hypertension 




Hypertension is diagnosed as a BP of > 140/90 mmHg. The BP should be ideally measured 
twice by instruments validated for use in pregnancy either automated, liquid-crystal or mercury 
sphygmomanometer. 
Chronic hypertension (CH) 
Chronic hypertension is hypertension predating the pregnancy. As some women will not have 
had their BP measured close to pregnancy, in practice the diagnosis of CH is often made in 
the first trimester. 
Gestational hypertension (GH) and preeclampsia 
New onset of hypertension after 20 weeks’ gestation is characteristic of gestational 
hypertension and PE. The diagnosis of PE is made by hypertension and the coexistence of 
one or more of the following conditions: 
Proteinuria 
The presence of significant proteinuria defined as presence of more than 300 mg/day protein 




Maternal organ dysfunction 
This is characterised by: 
• Renal insufficiency: characterised by serum creatinine levels of > 90 mol/L or 1.02 
mg/dL 
• Liver involvement: characterised by elevated transaminases with levels at least twice 
the upper limit of normal range with or without right upper quadrant or epigastric 
abdominal pain 
• Neurological complications: characterised by hyperreflexia accompanied by 
clonus; severe headache accompanied by persistent visual scotoma; blindness, stroke 
or eclampsia 
• Haematological complications: characterised by platelet count below 150,000/dl 
 
Utero-placental dysfunction 
This is characterised by presence of fetal growth restriction. 
 
Gestational hypertension (GH) is diagnosed when hypertension develops de novo after 20 
weeks’ gestation and is not accompanied by any of the above features. PE superimposed on 
CH is diagnosed when the hypertension is accompanied by one or more of the above features. 
White coat hypertension 
This is hypertension uniquely diagnosed in clinical setting with normal BP measurements 
obtained in the home setting. This diagnosis can be confirmed by carrying out 24 hour 
ambulatory BP monitoring.  
Gestational proteinuria 
This is diagnosed as a finding of significant proteinuria as per the above definitions without the 
accompanying hypertension or primary renal disease. 
1.2.2 Classification of PE 
There remains much debate on how the disorder should be classified. Some classifications 
define PE as pregnancy induced hypertension in association with evidence of multi-organ 
dysfunction; proteinuria, or other complications such as renal insufficiency, liver disease, 
neurological problems, haematological disturbance, or fetal growth restriction (North et al., 
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2011). Other authors have distinguished between proteinuric and non-proteinuric PE, reporting 
that the former carries a worse prognosis than non-proteinuric PE, which is in turn thought to 
carry a worse prognosis than gestational hypertension alone (Homer et al., 2008). 
 
Table 1.3 The revised ISSHP definition of preeclampsia (Tranquili et al., 2014). 
Hypertension developing after 20 weeks co-existing with new onset of one or 
more of the following features 
• Proteinuria 
• Maternal organ dysfunction 
                - Renal insufficiency 
                - Liver involvement 
                - Neurological complications 
                - Haematological complications 
• Utero-placental insufficiency 
                - Fetal growth restriction 
 
Opinions differ widely over whether early and late variants of PE are the same disease, or 
whether they have a completely different pathophysiology to each other. In general, the 
maternal risk factor profiles vary between the two variants. An alternative hypothesis is that PE 
is a spectrum disorder, and the more severe the disease is, the earlier the gestation at which 
the delivery will be. A novel approach for screening for PE involving multiple maternal 
characteristic variables and biomarkers in which, the gestation at the time of delivery for PE is 
treated as a continuous rather than a categorical variable. This method, based on a survival 
time model, allows estimation of individual patient-specific risks of PE requiring delivery before 
a specified gestation. This approach considers a situation that if a pregnancy continued 
indefinitely, all women would develop PE. Whether they develop PE or not depends on the 
competition between delivery before or after development of PE (Wright et al., 2012). This 
theory has contributed significantly to the most successful approach to preeclampsia prediction 
and will be discussed further in the subsequent chapters. 
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1.3 Pathogenesis of Preeclampsia 
Although the exact cause of PE remains elusive, the condition is thought to be predominantly 
due to defective implantation of the placenta within the uterine endometrium. The pathogenesis 
is hypothesised to occur in two main phases. The first phase begins with abnormal 
placentation, while the second phase is characterised by an abnormal maternal endothelial 
response, resulting in the clinical manifestations of the condition including hypertension, 
proteinuria and oedema. Figure 1.3 summarises the pathogenesis of PE. 
1.3.1 Placental phase 
Normal Placentation of Pregnancy 
The uterus is supplied by the two uterine arteries, with some collateral circulation from the 
ovarian arteries. The circumferential delivery of blood to the uterus is achieved via the arcuate 
arteries that arise from the uterine arteries (Figure 1.1). These vessels penetrate the 
myometrium of the uterus in the form of radial arteries and give rise to  
 
 
Figure 1.1 The blood supply to the uterus (taken from http://emedicine.medscape.com) 
the basal and spiral arteries, which supply oxygenated blood to the myometrium, decidua and 
the intervillous spaces in the placenta during the pregnancy. The placenta develops primarily 
from fetal derived trophoblastic cells. The trophoblast is the first cell linage to differentiate at 
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the stage of the blastocyst, occurring approximately 6 days post conception (Huppertz and 
Herrler, 2005). Upon blastocystic implantation, these trophoblastic stem cells undergo mitosis 
and differentiate into two types: the cytotrophoblasts, which are the precursors to all 
subsequent trophoblast cells and at the attachment site, the syncytiotrophoblasts; those 
responsible for the invasion into the decidua, and in particular, the maternal spiral arteries. 
Under the influence of certain growth factors, including vascular endothelial growth factor 
(VEGF) and placental growth factor (PlGF), a definitive blood supply is established with both 
the formation of new vessels (vasculogenesis) and branching from existing vessels 
(angiogenesis). Approximately 4-6 weeks post-conception, the cytotrophoblasts differentiate 
into invasive extravillous cytotrophoblasts and disrupt the maternal vascular integrity by 
migrating into the decidua and invading the maternal spiral arteries – a process known as 
endovascular invasion. Interstitial invasion also occurs, in which these differentiated cells bury 
through into the myometrium underlying the placental bed. Initially, these interstitial 
cytotrophoblasts remain adjacent to the spiral arteries, but from 8 weeks of gestation onwards, 
invasion of the inner third of the myometrium occurs and the cytotrophoblasts become more 
broadly distributed (Pijnenborg et al., 1991). The fusion of these interstitial cytotrophoblasts 
with the formation of multi-nucleated giant cells is thought to influence the prevention of further 
myometrial invasion (Pijnenborg et al., 1983). 
Endovascular trophoblasts are found within the lumen of the spiral arteries from 4 weeks of 
gestation and they migrate towards the proximal part of the vessel (Pijnenborg et al., 1991). 
They line the endothelium and disrupt the walls of the intra decidual portion of the spiral 
vessels, thus destroying the muscular and elastic integrity of the media. The vessel wall is 
eventually replaced by a fibrinoid material originating from both, fibrin in the maternal blood 
and proteins secreted by the trophoblast. These small-diameter high resistance spiral arteries 
become grossly dilated, funnel-shaped, flaccid utero placental arteries with diameters 
increasing from 15-20 to 300-500 m. The high resistance in the utero placental circulation is 
transformed to a circulation of low resistance and higher volume than that which is present in 
the pre-pregnancy state. This fall in vascular resistance is facilitated by the loss of normal 
vasomotor control of the spiral arteries as the muscular and neural layers are no longer intact. 
This allows the required ten-fold increase in uterine blood flow to meet the nutritional needs of 
the developing fetus. Crucially, this physiological process is thought to occur in two stages: the 
initial wave of trophoblastic invasion, from approximately 8 weeks of gestation, involves the 
decidual portion of the spiral arteries. The second wave occurs at the junctional zone of the 
spiral arteries at the level of the myometrial segments and occurs at 14-24 weeks of gestation 
(Lyall, 2002).  
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Placentation in Preeclampsia 
In PE, the physiological processes of vasculogenesis and angiogenesis described, as well as 
the transformations of the spiral arteries, do not occur as they should. There is inadequate 
invasion of the placenta by the cytotrophoblastic cells at the levels of both the decidua and the 
myometrium (Khong et al., 1986). Even though 50-70% of the spiral arteries display some form 
of invasion, this invasion is confined to the decidual part of the vessels. It is the second wave 
of invasion that appears to be defective, as the myometrial segments remain significantly 
unphased (Brosens et al., 1972; Gerretsen et al., 1981; Meekins et al., 1994a). 
Atherosclerosis is also a common histological feature found in placentas of pregnancies 
complicated by PE (Sheppard and Bonnar, 1981). Macrophagic infiltration of the vessel walls 
causes a fibrinoid necrosis and a perivascular mononuclear cellular infiltrate (Pijnenborg et al., 
1991). The walls of the vessels of the utero placental circulation are subjected to a higher 
density of lipoproteins (Meekins et al., 1994b) and within these vessels, micro thrombi 
contribute to the macroscopic infarction of the placenta (Salafia et al., 1995).  
This acute atherosis is not unique to PE. It is also observed in the placentas of pregnancies 
affected by fetal growth restriction, antiphospholipid syndrome and spontaneous miscarriage. 
The former, with or without PE, can be associated with the failure of trophoblastic invasion of 
the maternal spiral arteries (Frusca et al., 1989). 
Research has shown that high resistance in the Doppler studies of uterine arteries, in 
pregnancies affected by PE, correlates well with histological findings from placental bed 
biopsies of such pregnancies (Olofsson et al., 1993; Meekins et al., 1994a; Sagol et al., 1999).  
Not all cases of PE are associated with impaired placentation (Pijnenborg et al., 1991; Meekins 
et al., 1994a), however, a number of studies suggest that the gestational time of onset is 
related to the degree of the placental histological insult (Moldenhauer et al., 2003; Egbor et al., 
2006). In late PE, the placental morphology and histology are more likely to resemble those of 
normotensive pregnancies. It has been shown that a diagnosis of PE is more likely to be made 
prior to 32 weeks of gestation in those with progressive utero placental circulation compromise 
(Ghidini et al., 1997).  
There is considerable overlap in the degree of placental vascular lesions between normal and 
PE pregnancies (Ghidini et al., 1997) and similarly, a degree of utero placental vascular 
pathology does not render a pregnancy destined to yield significant morbidity and/or mortality 
(Aardema et al., 2001). This has been corroborated by studies that have shown that 
trophoblastic invasion into the myometrial segments can still occur in PE (Sheppard and 
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Bonnar, 1981). Pijnenborg et al. (1991) showed that trophoblastic invasion of a vessel wall can 
vary in depth from affecting only a segment of the arterial wall to the whole circumference of 
the artery. However, the severity of changes within the spiral arteries does not necessarily 




Figure 1.2 Normal and abnormal placentation (taken from Kita and Mitsushita, 2008) 
In summary, there can be a significant disruption to the normal physiological placentation 
process that can diminish the quality and quantity of maternal revascularisation in pregnancies 
complicated by PE (Figure 1.2). The consequent high-pressure system restricts the necessary 
physiological increase in blood supply required by the developing fetus and poor utero 
placental perfusion ensues. Normal placentation may, however, be found in pregnancies 
affected by PE, thus the correlation between abnormal placentation and subsequent adverse 
pregnancy outcome is not exact. The insufficient trophoblastic invasion should be considered, 
therefore, more of a predisposing factor, with the maternal response syndrome contributing to 
the clinical signs of the disorder. 
1.3.2 Genetic factors 
A genetic predisposition to PE may be a factor for those that develop the disorder. Women 
with a positive family history have an estimated threefold risk for developing the condition 
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compared to those without a family history of PE (Arngrimsson et al., 1990; Duckitt and 
Harrington, 2005). 
The presence of such ‘preeclampsia susceptibility genes’ or a combination of these genes or 
their alleles may increase the risk of PE by altering the regulation of blood pressure and/or by 
influencing and modifying placental function (Cooper and Liston, 1979; Chesley and Cooper, 
1986). The proposed genetic models are either a single recessive gene or a single dominant 
gene (Cooper and Liston, 1979; Chesley and Cooper, 1986). There have been reported 
associations between PE and polymorphisms of various genes such as angiotensinogen, 
tumour necrosis factor-a (TNF-), factor V Leiden and the 5,10-methylenetetrahydrofolate 
reductase genes (Morgan et al., 1999; Lachmeijer et al., 2001; Benedetto et al., 2002; 
Heiskanen et al., 2002). 
In a recent systematic review of literature and meta-analysis (Human Genome Epidemiology 
Review [HuGE review]), the authors examined the association between maternal genotype 
and severe PE according to certain gene groups including immune, cell signalling, metabolic, 
thrombophilic and vasoactive groups. They analysed 57 studies which evaluated 50 genotypes 
in 5,049 cases and 16,989 controls and found that a high risk for severe PE was noted with 
coagulation factor V gene (proaccelerin, labile factor) polymorphism rs6025, coagulation factor 
II (thrombin) gene mutation G20210A, leptin receptor gene (LEPR) polymorphism rs1137100 
and the thrombophilic gene group (Fong et al., 2014).  
In another meta-analysis, the authors specifically examined the relationship between the risk 
of PE and two thrombophilia single-nucleotide polymorphisms (SNPs), the factor V G1691A 
SNP and prothrombin G20210A SNP. They examined 37 studies with 5,048 patients with PE 
and 6,796 controls and reported that both these polymorphisms are associated with increased 
risk of all types of PE, including severe PE (Wang et al., 2014). In this publication, the presence 
of a prothrombin 20210A polymorphism doubled a patient’s risk of developing PE and an 
approximate 3-fold increase in risk for severe PE. The authors discuss that although 
associations between gene polymorphisms and PE has been illustrated, to explore this further 
and establish a causal relationship, there is a need for larger prospective studies.  
1.3.3. Immunological factors 
As the placenta originates from fetal cells, there are both maternal and paternal derived 
antigens. In pregnancies unaffected by PE it appears that the maternal immune system 
tolerates the fetal antigens and mounts a modified immune response to allow acceptance of 
the semi-allogenic fetus. To facilitate this, there must be a change within immune pathways 




Figure 1.3 A summary of the pathogenesis of PE (Parikh and Karumanchi, 2008). 
Natural Killer (NK) cells, macrophages and dendritic cells are mediators of the innate immune 
system. NK cells have been shown to initiate smooth muscle remodelling of the maternal spiral 
arteries (Robson et al., 2011). Macrophages and dendritic cells act as major antigen presenting 
cells within the uterus. The presence of these cells permits the maternal immune system to 
adapt and thus prevent pregnancy loss. Studies of placental macrophages suggest that in 
pregnancies affected by PE, there are significantly more macrophages in this cohort’s 
placentas, and that macrophage infiltration is implicit in impaired trophoblast invasion (Zhang 
et al., 2013).  
It has been shown that in pregnancies with PE, an immunological cascade is activated 
producing a reaction to both the fetus and the placenta and particularly against the paternal 
portion of the trophoblasts (Dekker et al., 1998; Dekker and Robillard, 2005). It remains 
unanswered whether this immune reaction is a consequence of the abnormal placentation or 
if it is in fact, an aetiological factor (Djurisic and Hviid, 2014). 
There are two classes of human leukocyte antigens (HLA): class I and II. The class HLA Ia 
antigens (A, B and C) and HLA II (DR, DQ and DP) are concerned with antigen presentation 
and therefore in organ transplantation and autoimmunity. The HLA Ib (E, F and G) genes are 
primarily expressed in the extravillous trophoblast cells lining the placenta and by 
syncytiotrophoblast cells (Ishitani et al., 2003; Bhalla et al., 2006) and have drawn the attention 
of researchers for this reason. Uniquely, the HLA-G is expressed on the surface of the 
trophoblast. A possible altered maternal immune response against the paternally-derived 
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antigens on the trophoblast is hypothesised as a potential aetiological factor. Sargent et al. 
(2006) proposed that PE is a syndrome in which the first stage, the inadequate trophoblastic 
invasion leads to depressed expression of HLA-G causing a diminished stimulation of decidual 
NK cells that are essential for the production of immunoregulatory cytokines and angiogenic 
factors. The second stage involves leukocytes and the endothelium in a systemic inflammatory 
response type syndrome. This inflammatory stimulus is thought to originate in the placenta and 
may be caused by the release of necrotic and/or apoptotic syncytiotrophoblasts into the 
maternal circulation. 
Epidemiological data supports these hypotheses as PE is more common in a first pregnancy, 
the risk for PE decreases with subsequent pregnancies (with the same father), changing 
partners results in a loss of the parity protection against PE (Robillard et al., 1999; Li and Wi, 
2000) and lastly, donor insemination techniques and oocyte donation both increase the 
likelihood for the development of the condition (Smith et al., 1997; Wilson et al., 2003).  
1.3.4. Inflammation and oxidative stress 
Normal pregnancies are associated with a maternal systemic inflammatory response, and this 
response is exaggerated in preeclamptic pregnancies (Redman et al., 2003). This 
inflammatory state activates several associated pathways, including those involved in oxidative 
stress. One of which is the production of reactive oxygen species (ROS) leading to oxidative 
stress when the inherent anti-oxidant mechanisms in tissues are overwhelmed. In pregnancies 
with PE, the impairment in placentation leads to the sequence of placental hypoxia and re-
oxygenation causing an increased production of ROS, which in turn contributes to the oxidative 
stress (Burton and Jauniaux, 2011). This oxidative stress has been shown to be involved in 
vasculopathy and has therefore been postulated to be involved in preeclampsia development. 
Some work has evaluated the link with prevention of preeclampsia with anti-oxidants such as 
vitamins C and E. This is described in detail in section 1.5.3. In summary, placental hypoxia 
leads to oxidative stress causing a release of proinflammatory cytokines and trophoblast debris 
into the circulation, contributing to the pathophysiology of PE (Cindrova-Davies et al., 2007). 
Placental oxidative stress resulting from the ischaemia–reperfusion injury is involved in the 
pathogenesis of PE (Gupta et al., 2005). Placental lipid peroxidation levels are significantly 
higher in the placentas of PE (Walsh et al., 2000; Atamer et al., 2005, Vanderlelie et al., 2005). 
Dyslipidaemia early in pregnancies complicated by PE can lead to the accumulation of very 
low-density lipoproteins (VLDL) in the subendothelial space. These are then oxidised to form 
highly reactive oxidised LDL which disrupt the membrane proteins and phospholipids and 
increase the expression of signalling molecules which recruit inflammatory cells. The injured 
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membrane alters endothelial function while monocytes take up oxidised LDL to form foam cells 
and eventually the fatty streak characteristic of atherosclerosis (Roberts and Cooper, 2001). 
In PE, the reduced reserve in net anti-oxidant activity exacerbates this damage caused by 
these oxygen free radicals. 
1.3.5. Endothelial dysfunction 
Although multiple aetiologies have been attributed to causing PE, it is placental hypoperfusion 
leading to ischaemia and necrosis/infarction that is thought to be the end point that results in 
the clinical manifestations of this syndrome. Endothelial cell activation is hypothesised to be a 
prominent pathophysiological feature of PE. This is underlined by the increased vascular 
resistance, which is also key feature of the disorder. It has been well documented that impaired 
placentation and the resulting placental hypoxia can lead to intravascular inflammation and 
consequent activation or repression of endothelial cell function (Redman, 1991; Gervasi et al., 
2001; Redman and Sargent, 2003; Myatt and Webster, 2009; Saito and Nakashima, 2014). 
The consequent endothelial dysfunction alters the equilibrium of angiogenic and anti-
angiogenic proteins. The altered concentration of these proteins further exacerbates the 
endothelial dysfunction established by intravascular inflammation (Luttun et al., 2002; Maynard 
et al., 2003; López-Novoa, 2007; Widmer et al., 2007; Zhou et al., 2011; Murphy et al., 2013). 
The damaged placental tissue releases receptor proteins such as soluble fms-like tyrosine 
kinase (sFlt-1), which is a protein produced by the syncytiotrophoblast and is formed by 
alternative splicing of the Flt-1 gene. It antagonises the actions of proangiogenic growth 
factors, such as VEGF and PlGF (Kendall and Thomas, 1993; Huppertz et al., 2008), by 
attaching to the transmembrane receptors, thus preventing these proangiogenic factors from 
interacting with their receptors (Maynard et al., 2003; Levine et al., 2004; Romero et al., 2008; 
Taché et al., 2011). 
VEGF is a protein released by many cell types including the cytotrophoblast and it is involved 
in angiogenesis and vasculogenesis. It is transcribed from the VEGF gene, which is located 
on chromosome 6, which also encodes for various isoforms of VEGF including PlGF (Romero 
et al., 2008; Cheng et al., 2013). These angiogenic factors are crucial in mediating increased 
vascular permeability, which includes angiogenesis, vasculogenesis and growth of endothelial 
cells (Yamazaki et al., 2006; Maharaj et al., 2008). VEGF is vital in the preservation of 
endothelial function in fenestrated endothelium, particularly in the brain, liver and renal 
glomeruli (Esser et al., 1998). Higher levels of sFlt-1 counteract vasodilatory effects of nitric 
oxide, which is induced by VEGF, resulting in maternal hypertension (Maynard et al., 2003).  
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Soluble endoglin (sEng) is another anti-angiogenic factor implicated in the pathogenesis of PE. 
It is a surface receptor of transforming growth factor-β1 (TGF-β1), which induces growth and 
proliferation of endothelial cells (Venkatesha et al., 2006). Its anti-angiogenic properties are 
achieved by preventing the binding of TGF-β1 to its receptors on endothelial cells thereby, 
compromising their function and leading to impairment in production of nitric oxide (Levine et 
al., 2006).  sEng amplifies vascular damage mediated by sFlt-1 and the two together 
synergistically, can lead to severe vascular damage, nephrotic syndrome, proteinuria and fetal 
growth restriction (Venkatesha et al., 2006). Studies have shown that when sEng is 
administered to rodents, it induces a severe preeclampsia-like disorder (Maynard et al., 2011). 
It is the imbalance of these critical angiogenic proteins that cause systemic vascular 
dysfunction, capillary leaking and vasospasm, leading to the clinical spectrum of preeclampsia. 
Endothelial cell dysfunction affects vascular tone vasospasm and platelet activation and 
Romero et al. (1988) showed that even prior to the onset of hypertension, platelet dysfunction 
and thrombocytopaenia can be present. There are also alterations in the levels of prostacyclin 
and thromboxane A2. Prostacyclin is a vasodilator and inhibits platelet aggregation in contrast 
to thromboxane A2, which constricts blood vessels and promotes platelet aggregation 
(Romero et al., 1988). Prostacyclin concentration in maternal blood and urine in pregnancies 
with PE is reduced (Bussolino et al., 1980) and as expected, there is an increased production 
of thromboxane A2 with this disorder (Walsh, 1985). Consequently, there is increased platelet 
activation, resulting in platelet aggregation and formation of thrombi in the microcirculation of 
different organs, which is a major contributor to pathogenesis of PE (Romero and Duffy, 1980). 
 
1.4 Prediction of Preeclampsia 
 
1.4.1 Background 
PE and eclampsia are major causes of maternal mortality in the UK (Knight et al (Eds)., on 
behalf of MBRRACE-UK, 2016) although there has been a significant reduction in maternal 
mortality rates over the last 50 years. The traditional method for early detection and diagnosis 
of PE is to serially measure blood pressure and assess the urine for protein at regular intervals 
at antenatal clinics.  For women with no predisposing risk factors to PE, the Preeclampsia 
Community Guideline (PRECOG) (Milne et al., 2005) recommends following the National 
Institute for Health and Care Excellence (NICE) antenatal care for uncomplicated pregnancy 
guidelines (2008). However, if they have one or more risk factors (Table 1.4), they should be 
reviewed by a healthcare professional at least every 3 weeks between 24 to 32 weeks’ 
gestation and a minimum of every two weeks from 32 weeks’ gestation to delivery (Milne et 
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al., 2005). This approach is not useful for predicting or identifying high-risk women that are 
likely to go on to develop PE. Although recognition of maternal risk factors is useful in clinical 
practice, it cannot be used reliably to screen and predict PE (Wallenburg, 2001). In a statement 
published in 2017, which reaffirms the conclusions of their published guidance on the 
management of hypertensive disorders in pregnancy (ACOG, 2013), ACOG advocates there 
are no accurate, predictive tests at this time to determine whether a woman will develop 
preeclampsia and therefore continues to recommend against other methods for predicting PE. 
This document states that a detailed medical history and routine blood pressure 











• PE in any previous pregnancy 
• Ten years or more since last delivery 
Age 40 years or over 
Body Mass Index of 35 or more 
Family history of PE (mother or sister) 
Booking diastolic BP >80mmHg 
Booking proteinuria (of ≥ 1+ on more than one occasion or quantified at ≥ 0.3g/ 24 hr) 
Multiple pregnancy 
Certain underlying medical conditions 
• Pre existing hypertension 
• Pre existing diabetes 
• Pre existing renal disease 
• Antiphospholipid antibodies 
 
 
In addition, NICE (2008 and 2010) published guidelines for antenatal care in the UK and 
recommended that a woman’s level of risk for PE, based on her demographics and factors in 
her medical history, should be determined at the initial booking appointment and her 
subsequent intensity of antenatal care should be tailored according to this assessment of risk 
(Table 1.5). According to ACOG (2015), the risk factors for PE are nulliparity, age> 40 years, 
BMI ≥30 kg/m2, conception by in-vitro fertilization, history of previous pregnancy with PE, family 
history of PE, chronic hypertension, chronic renal disease, diabetes mellitus, systemic lupus 
erythematosus or thrombophilia. The ACOG (2013) had previously specified their indications 
for the initiation of aspirin prophylaxis (Table 1.5).  No available data exists on the performance 
of such a recommended screening strategy which treats each risk factor as separate screening 
tests. Such an approach to the screening of PE is likely to result in falsely classifying a large 
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number of pregnant women as screen-positive who will need more frequent antenatal 
monitoring, thereby undermining the very purpose of screening. In turn, it also creates a 
substantial and possibly avoidable strain on the healthcare system.  








-  Age ≥40 years 
-  Nulliparity 
-  Pregnancy interval of more  
   than 10 years 
-  Family history of PE 
-  Previous history of PE 
-  Body Mass Index of 30 Kg/m2    
   or above 
-  Pre-existing vascular disease     
   such as hypertension 
-  Pre-existing renal disease 
-  Multiple pregnancy 
 
 
High Risk Factors 
- Hypertensive disease 
during a previous 
pregnancy 
- Chronic kidney disease 
- Autoimmune disease 
(SLE/APS) 
- Pre-existing diabetes 
- Chronic hypertension. 
 
Moderate Risk Factors 
- First pregnancy 
- Age >40 years 
- Pregnancy interval >10 
years 
- BMI >35kg/m2 at 1st visit 
- Family history of PE 
 
 
- History of PE in two or 
more previous 
pregnancies  
            or  
- PE requiring delivery<34 
weeks’ gestation 
 
* More frequent blood pressure measurements should be considered for pregnant 
  women with above risk factors 
^ Aspirin 75mg daily until delivery 
± Aspirin 60-80mg daily 





1.4.2 Maternal demographic factors and obstetric history 
Maternal age 
There is no shortage of studies published that have suggested there is an increase in the risk 
of PE with advancing maternal age. Previous studies, which used maternal age with cut-offs 
at either 35 or 40 years of age, have shown a 2-fold increase in the risk of developing PE 
(Bianco et al., 1996; Lawoyin and Ani, 1996; Lee et al., 2000; Chen et al., 2000). The risk for 
PE also appears to increase more abruptly after the mid-30s in another study (Saftlas et al., 
1990) and similarly reported in a study by Mittendorf et al., (1996) the risk for PE increases by 
30-40% for every additional year past the age of 34 years.  
These findings were further corroborated in a study which confirmed the association of 
advanced maternal age with PE and this risk of PE was significantly higher in mothers older 
than 40 years compared to younger mothers. This association remained statistically significant 
regardless of adjustment for parity (Ziadeh and Yahaya, 2001). Another study that reported 
this association also examined the risk factors for PE in a multivariate approach, thus 
accounting for confounding effects and interactions, and reported that the risk for late onset 
PE increases by 4% every year over the age of 32 years (Poon et al., 2010). Advancing age 
is not only associated with PE but also their risk of developing early PE is higher than 
developing late PE (Khalil et al.,2013a). 
Parity & Change of Partner 
In primigravidas, the elevated risk of developing PE is reported widely. In fact, it is reported to 
increase this likelihood 3-fold (Duckitt and Harrington, 2005). In a systematic review of 26 
studies, researchers found that this elevated risk for PE remained even after adjusting for other 
risk factors such as maternal age, race and body mass index and the summary adjusted odds 
ratio was 2.71 (Luo et al., 2007). Interestingly, women who have previously conceived, and 
even after a miscarriage, appear to have some degree of protection against PE (Dekker et al., 
1998). This can be explained by the immune maladaptation hypothesis which states that the 
fetal-placental unit contains paternal antigens that provoke an abnormal maternal immune 
response in PE (Dekker, 1999). This hypothesis is strengthened as multiparity appears to 
reduce the risk of PE and with a change of partner, this protective effect is lost (Robillard et al., 
1993). It is thought that regular sperm exposure over a prolonged period prior to conceiving 
may prime the mother’s immune system and therefore creating a protective effect against PE 





It is also possible that the increased risk of PE associated with a change of partner may in fact 
be, attributable to a longer inter-pregnancy interval. The importance of the inter-pregnancy 
interval comes from a cross-sectional study which reported a significant increase in the risk of 
PE in women with inter-pregnancy intervals of more than 59 months compared with those with 
intervals of 18-23 months (Conde-Agudelo et al., 2000). A large Norwegian population study 
by Skjaerven et al. (2002) examining 550,000 women who had two or more singleton deliveries 
and 200,000 women who had three or more singleton deliveries demonstrated an association 
between the risk of PE and the inter-pregnancy interval is more significant than the association 
between the risk and a change of partner. More specifically, the risk in a second or third 
pregnancy is directly related to the inter-pregnancy interval. When this interval is 10 years or 
more, the risk of developing PE is similar to that of a nulliparous woman. After adjusting for the 
possibility of a change of partner, maternal age and year of delivery, the probability of PE is 
increased by a factor of 1.12 for each year increase in the inter-pregnancy interval. 
Parous women with history of previous preeclampsia 
Results from observational studies suggest that having had PE increases the risk of recurrence 
in subsequent pregnancies. This risk has been quoted to be between seven to ten times higher 
in a second pregnancy (Campbell et al., 1985; Sibai et al., 1986; Lie et al., 1998; Lee et al., 
2000; Mostello et al., 2002; Duckitt and Harrington, 2005). Inversely, women with PE in their 
second pregnancy are seven times more likely to have suffered from PE in their previous 
pregnancy compared to women in their second pregnancy who did not develop PE (Eskenazi 
et al., 1991; Stone et al., 1994). 
Quantifying such recurrence risks has proven more difficult. In a meta-analysis that examined 
the recurrence of hypertensive disorders in pregnancy, the authors examined data from 94 
studies including more than 99,000 pregnancies. They found the recurrence rates for 
hypertensive disorders in pregnancy, PE and GH were 20.7%, 13.8% and 8.6%, respectively. 
This study also found an inverse relationship between the gestational age at delivery in the 
first pregnancy and the risk of PE in a subsequent pregnancy (van Oostwaard et al., 2015). 
A history of PE doubles the risk of developing early PE (<32 weeks) in a subsequent pregnancy 
as opposed to late PE (Odegard et al., 2000). There are other studies reporting their results 
on the recurrence risk for a subsequent early PE (<34 weeks) for those a previous history of 
early PE in the index pregnancy. This risk ranges from 5% to 17% (van Rijn et al., 2006; 
Langenveld et al., 2010). In a systematic review examining the risks of early delivery at <34 
weeks following early PE in the first pregnancy, the authors reported results from 11 studies 
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including 2,377 women and found that the pooled recurrence risk for early disease is 
approximately 8% (Langenveld et al., 2011). 
Assisted reproductive technologies 
There are multiple studies showing that assisted reproductive techniques (ART) double the 
risk for PE (Maman et al., 1998; Jackson et al., 2004; Shevell et al., 2005; Lambert-Messerlian 
et al., 2006; Trogstad et al., 2009). Whether in vitro fertilisation (IVF) and simple ovulation 
induction inflict the same susceptibility to the disorder, remains unclear. The evidence is 
conflicting as one large observational study has shown that it is IVF that increases the risk for 
PE and not ovulation induction (Shevell et al., 2005) and another case-control study has found 
that both techniques are equally as likely to contribute to developing hypertension in pregnancy 
(Maman et al., 1998). On the contrary, Trogstad et al. (2009) has reported that it is ovulation 
induction rather than IVF that increases the risk of PE by two-fold. 
A cohort study of 47,088 pregnancies following ART showed that the risk of PE was higher in 
IVF pregnancies compared to pregnancies conceived spontaneously and, the risk was even 
higher in frozen-thawed cycles compare to fresh cycle pregnancies (Opdahl et al., 2015). 
Those who undergo donor IVF appear to have a higher risk for PE than those women having 
autologous ovum IVF (Simeone et al., 2014). There is also some evidence from IVF 
pregnancies with ovum donation that there is an altered extravillous trophoblast and 
immunological changes in decidua basalis which may impede the modification of the spiral 
arteries (Nakabayashi et al., 2015). A systematic review of 19 studies including more than 
86,000 pregnancies supported these findings by showing that the risk of PE is higher in oocyte 
donation IVF cycles compared to the other methods of ART and natural conception 
(Masoudian et al., 2015). 
Racial origin 
Extensive evidence in the literature clearly shows the association between certain racial origins 
and PE. A small series performed by Eskenazi et al. (1991) demonstrated that Afro-Caribbean 
race is associated with a 12-fold increase in the risk of PE but numerous larger studies suggest 
this number to be closer to a 20-50% increase in the risk (Mittendorf et al., 1996; Sibai et al., 
1997; Knuist et al.,1998; Mostello et al.,2002; Caughey et al., 2005). The risk for PE is also 
higher in women of South Asian origin. These differences in risks for PE also mirror the 
different metabolic profile of non-pregnant women, who have an increased susceptibility to 
cardiovascular disease. Both Afro-Caribbean and South Asian women are more susceptible to 
developing chronic hypertension and cardiovascular disease. Afro-Caribbean women are more 
likely to suffer a stroke and renal failure whereas South Asian women are more at high-risk of 
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coronary heart disease (Cappuccio 1997a; Cappuccio et al., 1997b; Ramaraj and Chellapa 
2008).  
In contrast, women of East Asian origin have a significantly lower risk of PE compared to 
Caucasian women. A retrospective cohort study including 67,746 pregnancies examining the 
risk of developing PE reported that in East Asian women of Chinese descent have a 
significantly lower risk compared to Caucasian women and the possible explanations for this 
difference could be attributed to the difference in BMI and lifestyle factors such as length of 
cohabitation with partner (Xiao et al., 2014).  
In a large prospective observational cohort study of more than 79,000 singleton pregnancies 
that looked at the association of maternal race with pregnancy outcomes, reported that the risk 
of PE was significantly higher in women of Afro-Caribbean and South Asian racial origin 
compared to Caucasian women. This increase in risk remained significant even after adjusting 
for other confounding factors. In fact, after chronic hypertension, Afro-Caribbean race was the 
second highest risk factor associated with risk for developing PE with an OR of 2.60 (Khalil et 
al., 2013b). 
Cigarette smoking 
There is little doubt that cigarette smoking has an adverse effect on pregnancy. It has a known 
association with chronic lung disease, preterm delivery and placental abruption, and it is also 
associated with an increased risk of fetal complications such as stillbirth, fetal growth restriction 
(FGR), placenta praevia and spontaneous miscarriage.  
However, there is evidence in the literature suggesting that the risk of PE is reduced in women 
who smoke cigarettes during pregnancy. A systematic review of 28 cohort and 7 case-control 
studies that included over 800,000 women, reported that cigarette smoking in pregnancy 
reduces the overall risk of PE by 30% (Conde-Agudelo et al., 1999). In an inverse dose-
response relationship manner, the risk of PE declined as the number of cigarettes smoked 
daily during the pregnancy increased. A meta-analysis of 9 cohort studies showed that 
smokers of less than 10 cigarettes per day and 10 or more cigarettes per day had 20% and 
30% reductions, respectively, in the risk of PE. Similar findings were observed with data pooled 
from 3 case-control studies (10% and 40%, respectively) (Conde-Agudelo et al., 1999). 
The GOPEC (Genetics of Pre-Eclampsia) consortium analysed over 1000 women with 
moderate to severe preeclampsia in a multi-centre study, and carried out a sub-analysis to 
analyse the relationship between smoking and PE. They found the risk of developing eclamptic 
seizures was increased five-fold in smokers compared to non-smokers, suggesting that 
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although smokers are less likely to develop PE, but if they do, they develop a more severe 
form of the disorder (Pipkin FB, Genetics Preeclampsia Consortium, 2008). 
Another interesting observation documented from a Swedish population study was that a 
change in smoking habits during pregnancy can affect the risk for PE. Women who reported 
smoking at the first antenatal visit but stopped subsequently, did not have reduced rates of PE. 
However, those who reported no smoking initially, but were smoking at 30-32 weeks’ gestation 
had reduced rates of PE, suggesting that smoking in the second half of pregnancy has a 
protective effect of the development of PE (Wikstrom et al., 2010).  
Family history of preeclampsia 
The risk for PE appears to be increased 3-4 fold when there is a history of PE in the family i.e. 
mother or sister (Arngrimsson et al., 1990; Cincotta and Brennecke, 1998). Arngrimsson et al. 
(1990) analysed 94 families spanning over at least 3 generations, the authors reported that the 
prevalence of PE is higher in daughters-in-law (23% vs 10%). There are other reports which 
have suggested that a family history of PE in a mother, sister or both triples the risk of PE 
(Cincotta and Brennecke, 1998). 
Obesity  
Obesity has gradually become a huge public health issue, having profound impacts on all 
aspects of medicine. Unsurprisingly, it is an important risk factor for developing PE. Numerous 
studies have shown that an elevated BMI as a risk factor confers a 2-4 fold increase in the rate 
of PE (Eskenazi et al., 1991; Stone et al., 1994; Mittendorf et al., 1996; Conde-Agudelo and 
Belizán, 2000; Mostello et al., 2002; Duckitt and Harrington, 2005). A Norwegian population-
based study, reported that a high pre-pregnancy BMI is not an independent risk factor for early 
PE but it increases the risk of late PE by two-fold (Odegard et al., 2000). 
Corroborating this evidence, another large prospective observational cohort study of more than 
45,000 singleton pregnancies, which examined the association of maternal BMI with 
pregnancy complications, it was reported that the risk of PE was higher with increasing 
maternal BMI. This study found, with univariate analyses that the risk was higher for late PE 
compared to early disease (Syngelaki et al., 2011). In another cohort study, the high BMI was 
stratified to assess whether this impacted the association between maternal BMI and risk of 
severe PE. The authors reported that there was no significant difference between four BMI 
categories with regard to risk of severe PE. These categories were normal (BMI 18.5-24.9) 
overweight (BMI 25-29.9, obese (BMI 30-39.9 and morbidly obese (BMI ≥40). The risk of 
severe late PE is increased once a woman enters the overweight category (Durst et al., 2015).  
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There is evidence that maternal serum levels of adiponectin, a biomarker for obesity, in the 
first trimester are significantly higher in women who subsequently develop early PE than those 
who develop late PE and those who remain normotensive. The authors report that adiponectin 
levels are not related to biophysical and biochemical markers of impaired placentation such as 
uterine artery PI and serum PAPP-A. The altered levels of adiponectin may be secondary to 
an alternate pathophysiological process such as endothelial dysfunction (Nanda et al., 2011). 
Pre-existing medical conditions 
There are certain medical conditions that are known to predispose a woman, when pregnant, 
to developing PE. These include type I diabetes mellitus, pre-existing chronic hypertension, 
renal disease, autoimmune diseases, such as systemic lupus erythematosis, and anti-
phospholipid syndrome. Duckitt and Harrington (2005) analysed these conditions and their 
association with PE in a systematic review and they reported summary relative risks for PE 
given these pre-existing medical conditions. 
Diabetes mellitus 
Pre-pregnancy type I diabetes mellitus has been shown in studies to increase the risk of 
developing PE to over three times the normal population risk (Garner et al., 1990; Ros et al., 
1998; Lee et al., 2000).  
Chronic hypertension 
Pre-existing hypertension has been shown to double the risk for PE (Conde-Agudelo et al., 
2000). In another study, Catov et al. (2007), examining more than 70,000 women from the 
Danish National Birth Cohort, have shown that primiparous women with pre-existing 




Table 1.6 Relative risks of pre-existing medical conditions for the development of preeclampsia 
(modified from Duckitt and Harrington, 2005). 
 Pre existing condition Type of study N Unadjusted RR 
(95% CI) 
 








Systolic ≥ 130mmHg at booking 












Cohort 1,802 9.72 (4.34-21.75) 
Anti-phospholipid antibodies Case control 760 6.12 (0.35-108.35) 
 
Autoimmune disease 
A matched case-control study showed that women who developed PE were six times more 
likely to have an autoimmune disease (Stamilio et al. 2000). The presence of anti-phospholipid 
antibodies (anti-cardiolipin antibodies and/or lupus anticoagulant) has been observed to 
significantly increase the risk of developing PE in both cohort and case-control studies (Branch 
et al., 1989; Sletnes et al., 1992; Pattison et al., 1993; Yasuda et al., 1995; Dreyfus et al., 
2001). 
Renal disease 
Davies et al. (1970) found that women who developed PE had a higher prevalence of renal 
disease was (5.3% vs 1.8%). Another study compared women with renal disease (n=69), 
based on a history of urinary tract infections, with a prospective control population matched for 
age, parity, smoking and date of delivery and has demonstrated a three-fold increase in the 
risk of developing PE, in women with a history of urinary tract infections compared to controls 




1.4.3 Biophysical markers 
Uterine artery Doppler  
Doppler ultrasound assessing the resistance to blood flow in the uterine arteries correlates 
with both histological studies and also clinical severity of PE. Initially, this screening was 
performed in the second-trimester using uterine artery Doppler, but it has also been shown to 
be effective to varying degrees all through pregnancy (O’Gorman et al., 2016). This biophysical 
marker provides a useful non-invasive method for the assessment of the utero placental 
circulation. Studies have shown that a significant decrease in resistance in the spiral arteries 
occurs with advancing gestation, which is in keeping with physiological changes (Carbillon et 
al., 2001). The impedance to flow continually diminishes up to 24-26 weeks of gestation due 
to the trophoblastic invasion of the spiral arteries and their conversion from narrow muscular 
vessels to low resistance wide non-muscular channels (Campbell et al., 1983). This fall in 
impedance could also be due to hormonal effect in pregnancy on the elasticity of arterial walls. 
Persistent high impedance to flow in the uterine arteries is evidence of poor placentation that 
manifests itself in the form of abnormal utero placental flow velocity waveforms. Histological 
examination of placental bed biopsies of pregnancies affected by PE are closely correlated 
with high resistance in uterine artery Doppler waveforms (Olofsson et al., 1993). Studies have 
shown that impedance to flow in the uterine arteries is increased in PE as a direct result of not 
being able to convert maternal placental arteries into low pressure vessels (Aardema et al., 
2001). 
 
Second-trimester uterine artery Doppler 
This method of screening from PE has evolved from a blind technique, using continuous wave 
Doppler (Hanretty et al., 1989) to real-time ultrasound in order to positively identify the 
appropriate vessels (Bower et al., 1993a,b). The correct vessel is identified using pulsed wave 
Doppler and the uterine artery blood flow is distinguished from adjacent high resistance internal 
iliac vessels and lower resistance arcuate arteries. The use of colour flow along with pulsed 







Figure 1.4 Transabdominal technique in obtaining uterine artery waveform at the crossover 
with iliac artery. 
The uterine artery can be identified by both transabdominal and transvaginal ultrasound. The 
former requires holding the transducer in the longitudinal axis and lateral to the uterus. In that 
position the scan shows the bifurcation of the common iliac artery into external and internal 
iliac arteries and there is apparent cross-over of the uterine artery and the external iliac artery 
(Figure 1.4) Transvaginally, the ultrasound probe is inserted into the lateral fornices and the 
uterine artery can be identified at the level of the internal cervical os (Figure 1.5). 
The pulse wave Doppler is applied to the identified vessel and flow velocity waveform is 
obtained. When 3 consistent waveforms are visualised, the image is frozen and the pulsatility 
indices are obtained by tracing these waveforms. The indices derived from the flow velocity 
waveforms are described below. The resistance index ranges between 0 and 1 and that the 
pulsatility index is always greater than 0. 
 
Resistance index  = (Peak systolic velocity - minimum diastolic velocity) 




Pulsatility index  = (Peak systolic velocity - minimum diastolic velocity)                                                                    
       Mean velocity 
  
 
Figure 1.5 Transvaginal technique in obtaining uterine artery waveform lateral to uterine cervix 
(Courtesy of Prof Nicolaides, Fetal Medicine Foundation). 
When the placentation process has completed by 22-23 weeks of gestation, the normal systolic 
waveform of the uterine artery has a slight upslope, with an abundance of diastolic flow 
velocity. In contrast, the high resistance waveform is characterised by steep systolic upslope 
with an early diastolic notch and reduced end diastolic flow velocity (Figure 1.6). Albaiges et 
al. (2003) compared velocity and impedance indices in a high-risk population. This population 
was defined by an increased uterine artery impedance > 95th centile or the presence of 
bilateral notching at a follow-up assessment from 24 weeks of gestation. The study showed 
that mean impedance indices perform better than velocity indices for predicting pregnancy 
adverse outcomes, irrespective of whether a notch was present or not. These quantitative 
uterine artery indices remove the operator-dependent assessment of notches and thereby 





Figure 1.6 Pulsed wave signals of uterine artery blood flow (a) normal waveform: there is a 
systolic upslope with an abundance of end-diastolic flow velocity (arrow); (b) abnormal 
waveform suggesting impaired placentation: there is a steeper systolic upslope compared with 
the normal waveform, with an early diastolic notch (yellow arrow) and reduced end-diastolic 
flow velocity (white arrow) (Courtesy of Prof Nicolaides, Fetal Medicine Foundation). 
Uterine artery Doppler has been shown to be better at predicting severe disease. Bilateral 
uterine notching at 24 weeks of gestation can identify 55% of women who will later develop 
PE and 81% of those with PE requiring delivery before 35 weeks of gestation (Harrington et 
al. 1996). Kurdi et al. (1998) found that bilateral notches and a mean resistance index of greater 
than 0.55 can identify 62% of women who later developed PE and 88% with PE requiring 
delivery before 37weeks. Using the pulsatilty index or the presence of bilateral notching, this 
yielded detection rates for all PE and PE prior to 34 weeks of 45% and 90% respectively 
(Albaiges et al.,2000). In a multicentre study of 30,639 patients, the mean uterine artery PI, 
obtained transvaginally, was found to be above the 95th centile in 77.2% of women who 
developed PE requiring delivery before 34 weeks’ gestation, in 35.9% of those delivering at 
34-37 weeks’ gestation and in 21.9% of those delivering after 37 weeks’ gestation (Yu et al., 
2008). 
First-trimester uterine artery Doppler 
As placentation starts in the first trimester, it appears logical that an abnormal utero-placental 
circulation observed in the second-trimester with uterine artery Doppler ultrasound, could also 
be detected with ultrasound in the first-trimester. Indeed, studies have shown that there is a 
good correlation between first and second-trimester uterine artery Doppler measurements.  
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These studies initially demonstrated that flow resistance in the uterine arteries increases with 
gestational age from 10 to 22 weeks and that flow in the second-trimester is influenced by the 
flow in the first-trimester (Jurkovic et al., 1991; Kaminipetros et al., 1991). The methodology 
and reproducibility of this apparent marker of placental dysfunction has been reported by 
Martin et al. (2001). 
There are a number of factors that can influence the raw values of uterine artery Doppler 
pulsatility indices in pregnant women. Therefore, the uterine artery PI value needs be adjusted 
for these associated maternal characteristics by converting it to a multiple of the median 
(MoM). These associations were studied in more than 6,500 pregnancies which reported that 
uterine artery PI decreased with gestational age and maternal BMI and was higher in women 
of Afro-caribbean racial origin, in nulliparous women and, importantly, in multiparous women 
with a previous history of PE (Plasencia et al., 2007). Taking these elements into consideration, 
allows a standardised approach to assessing the uterine artery PI.  
A combination of maternal history and uterine artery Doppler is an effective screening method 
for PE, in particular early PE, with a detection rate (DR) of about 80% for a false positive rate 
(FPR) of 10% (Plasencia et al., 2007; Poon et al., 2009a). A combination of first and second 
trimester screening using uterine artery Doppler can improve the prediction of PE as the 
decrease in impedance of placental blood flow between 12 and 23 weeks is steeper in normal 
placentation with a normal outcome than in those that develop PE. This approach could be 
implemented to follow-up women with a high PI at their first trimester scan (Plasencia et al., 
2008). 
Blood pressure 
Although hypertension is a secondary sign of PE, it is an important sign as it is an early 
indication of the disease. The importance of accurate measurements of maternal blood 
pressure (BP) antenatally cannot be overstated. It is the mainstay of early detection, prediction 
and diagnosis of hypertension in pregnancy. It has already been well documented that women 
destined to develop PE will have elevated BP in the first- and second-trimesters of pregnancy 
(Moutquin et al., 1985; Higgins et al., 1997; Poon et al., 2008 and 2011).  A systematic review 
that assessed the value of using BP measurements to predict PE, examined data from 60,599 
women including 3,341 cases with PE and concluded that mean arterial pressure (MAP) 
predicted PE reasonably well, with an area under the curve between 0.70 and 0.80. In contrast, 
systolic and diastolic BP and an increase of systolic and/or diastolic BP performed poorly in 
the prediction of PE with an area under the curve of <0.70 (Cnossen et al., 2008). In the studies 
in this review, there was considerable heterogeneity which included major differences in study 
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design, sample size, differences in use of machines used to measure BP, mixture of high-risk 
and low-risk populations and major differences in the DR between studies. These are 
significant limitations that contributed to the finding of this review. 
The use of mercury sphygmomanometers remains the gold standard for non-invasive BP 
monitoring. However, concerns for both their clinical performance and safety have been raised 
(Markandu et al., 2000). Inaccurate BP readings using this method can include inter observer 
error and terminal digit preference, the rate at which the cuff deflates, the use the appropriate 
size cuff, the inter-arm difference in BP, and the arm position and posture. Automated BP 
monitoring will mitigate many of these obstacles and allow simple, standardised and repeated 
measurements to be taken. However, their use still requires both the correct cuff size and 
patient positioning to achieve accurate measurements.  
In a large prospective screening study of more than 9,000 pregnancies at 11-13 weeks’ 
gestation, the performance of systolic BP, diastolic BP and MAP in screening for hypertensive 
disorders of pregnancy using validated automated devices was assessed.  Although systolic 
BP, diastolic BP and MAP were all found to be increased in women who developed PE, the 
MAP performed best as a marker with a DR for early PE increasing from 47% based on 
maternal factors alone to 76% based on a combination of maternal factors and MAP, at a FPR 
of 10% (Poon et al., 2011). As for uterine artery Doppler values, the MAP should be converted 
into a MoM by taking into account the significant independent influencing cofactors. These 
include the fetal crown-rump length (CRL), maternal body mass index (BMI), maternal age, 
smoking status and racial origin. 
Accurate measurement of MAP requires the adherence to a strict protocol (Poon et al., 2012). 
The patient should be in the sitting position with their arms supported at the level of the heart. 
A small (22 cm), normal (22 to 32 cm) or large (33 to 42cm) adult cuff should be used 
depending on the mid-arm circumference. A validated automated device should be used, and 
after five minutes rest, two measurements of blood pressure should be made in both arms 
simultaneously and the final MAP is calculated as the average of all four measurements. 
1.4.4 Biochemical markers  
There have been numerous biochemical markers studied and evaluated for clinical use in the 
prediction of PE (Table 1.7). At present, there is no single marker available to accurately 
diagnose or predict PE, which is not surprising, given the complexity of the disorder. The 
alterations in the levels of these markers are the sequelae of impaired placentation secondary 
to inadequate trophoblastic invasion of the maternal spiral arteries and impaired placental 
perfusion. As mentioned above, these manifestations cause ischaemic related damage with 
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the release of inflammatory factors, platelet activation, endothelial dysfunction, maternal renal 
dysfunction or abnormal oxidative stress. Maternal serum PAPP-A and PlGF are two 
biochemical markers that have been investigated extensively and have shown promising 
results in the early prediction of PE. They have both been shown to be useful in screening for 
Down’s syndrome at 11-13 weeks’ gestation and they are now part of a platform of automated 
machines that provide reproducible results within 30-40 minutes of sampling.  
Certain maternal and pregnancy characteristics can alter the crude serum concentration 
values of these metabolites and consequently, it is necessary to make adjustments for these. 
These include the fetal CRL, maternal weight, cigarette smoking status and ethnic origin. In 
addition, one must also consider the type of machine and reagents used for the assays and in 
order to achieve the most accurate results, the values should be expressed in multiples of the 
expected median (MoM) of the normal (Kagan et al., 2008a).  
Pregnancy associated plasma protein-A 
PAPP-A is a metalloproteinase insulin-like growth factor (IGF) binding protein secreted by the 
syncytiotrophoblast that plays an important role in placental growth and development. It 
enhances the mitogenic function of the IGFs. PE has been shown to be associated with a low 
level of circulating PAPP-A, which presumably is a consequence of a reduced availability of 
unbound IGFs to fulfil their functional role on a cellular level. PAPP-A is a well established 
biochemical marker in the screening of trisomies 21, 18 and 13. It is performed in combination 
with maternal age, fetal nuchal translucency thickness (NT) and maternal serum free ß-human 
chorionic gonadotrohpin (ß-hCG) at 11-13 weeks of gestation. All three trisomies are 
associated with increased maternal age, increased fetal NT and decreased maternal serum 
PAPP-A, but in trisomy 21 serum free ß-hCG is increased whereas in trisomies 18 and 13 this 
is decreased. In unaffected pregnancies the median free ß-hCG and PAPP-A is 1.0 MoM. In 
trisomy 21 pregnancies the median free ß-hCG is 2.0 MoM and the median PAPP-A is 0.5 
MoM whereas in trisomy 18 the respective values are 0.2 MoM and 0.2 MoM and in trisomy 
13 they are 0.5 MoM and 0.3 MoM (Kagan et al., 2008b, Nicolaides, 2011a). 
In chromosomally normal pregnancies, a PAPP-A value below the 5th centile (0.4 MoM) is only 
present in 8-23% of women with PE (table 1.5). Therefore alone, this is not an accurate predictive 
test for PE (Yaron et al., 2002; Smith et al., 2002; Dugoff et al., 2004; and Spencer et al., 2005). 
  
In clinical practice, when patients are found coincidentally to have a level of PAPP-A below 0.4 
MoM during routine first-trimester screening for trisomies, their obstetrician should be made 
aware of the increased risk for PE. At this level, the reported odds ratios for PE varied between 
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1.5 and 4.6. Although a low PAPP-A alone is not a strong indicator of PE, but combined with 
second-trimester uterine artery Doppler assessment, there is a significant improvement in 
detection of PE (Spencer et al., 2005, 2007). This had led to the recommendation that a low 
first trimester PAPP-A MoM in euploid pregnancies should be followed up further with 22- 24 
weeks uterine artery Doppler measurement to assess the risk of PE. In established disease, 
there are reports suggesting that the maternal serum PAPP-A level can be increased 




Table 1.7 Proposed maternal serum and urinary markers for the prediction of preeclampsia 






































Serum soluble fms-like 
tyrosine kinase 
Neurokinin B 
Placental growth factor 
































































Table 1.8 Summary of studies of PAPP-A in the prediction of preeclampsia. 
 
Author Total n (%) PAPP-A cut off 
centile (MoM) 
DR (%) OR or RR 
Ong et al., 2000 5,297 135 (2.6) 5th (-) 11.1 2.1 
Yaron et al., 2002 1,622 27 (1.7) 15th (0.5) 22.2 1.7 
Smith et al., 2002 8,839 331 (3.7) 5th (-) 10.6 2.3 
Dugoff et al., 2004 33,395 764 (2.3) 5th (0.42) 7.9 1.5 
Spencer et al., 
2005 
4,390 64 (1.5) 5th (0.42) 14.1 2.8 
Pilalis et al., 2007 878 13 (1.5) 5th (0.41) 23.1 1.6 
Spencer et al., 
2007 

















DR = detection rate; OR = odds ratio; RR = relative risk. 
Placental growth factor 
Placental growth factor (PlGF) is a glycosylated dimeric glycoprotein secreted by trophoblastic 
cells and is part of the angiogenic vascular endothelial growth factor family. It binds to vascular 
endothelial growth factor receptor-1, which has been shown to increase in pregnancy. PlGF is 
synthesised in villous and extravillous cytotrophoblast and has both vasculogenetic and 
angiogenetic functions. Its angiogenetic abilities have been speculated to play a role in normal 
pregnancy and changes in the levels of PlGF or its inhibitory receptor have been implicated in 
the development of PE (Maynard et al., 2003; Ahmad and Ahmed, 2004; Levine et al., 2004; 





Table 1.9 Studies comparing maternal serum PlGF in pregnancies with preeclampsia and 
normotensive controls in the first-trimester. 
                      Author  Preeclampsia 
 








Tidwell et al., 2001 5-15 14 20.1 25 58.5 <0.0001 





Thadhani et al., 2004 
 
11-14 40 23 80 63 <0.01 















609 0.991 <0.0001 
Crovetto et al., 2015 11-13 303 21.9* 
27.5^ 
9159 33.4 <0.05 
 
*Early PE statistically significant, ^Late PE 
Reduced levels of serum PlGF have also been shown to be present in the first-trimester of 
pregnancy (Table 1.9). Previous studies demonstrated that prediction of PE can be improved 
by combining the second-trimester uterine artery Doppler findings with maternal serum 
concentration of PlGF (Espinoza et al., 2007) and the anti-angiogenic protein soluble fms-like 
tyrosine kinase 1 (sFlt-1) (Stepan et al., 2007). Although reduced levels of PlGF are evident 
from the first-trimester, the significant increase in levels of sFlt-1 is only unmasked 
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approximately five weeks before the onset of PE (Levine et al., 2004). The authors also found 
that the PlGF concentrations steadily increase with gestational age, with levels peaking at 29-
32 weeks’ gestation and decreasing thereafter. In women with PE, the levels follow a similar 
pattern but were significantly lower than in controls from as early as 12-13 weeks of gestation 
(Levine et al., 2004).  
Screening by cell free DNA  
Following the discovery of fetal DNA in the maternal serum, several studies have reported that 
in women with established PE, the plasma or serum concentrations of both total and fetal cell 
free (cf)DNA are higher than in normotensive controls and the increase is particularly marked 
in those with severe PE (Lo et al., 1999; Zhong et al., 2001; Alberry et al., 2009; Miranda et 
al., 2013; Zeybek et al., 2013). These findings have been attributed to accelerated apoptosis 
of trophoblastic cells resulting from placental ischaemia (Lo et al., 1999) and reduced 
clearance of the cfDNA from the maternal circulation in women with PE (Lau et al., 2002).  
There is conflicting data as to whether these altered levels precede the onset of the disease. 
A recent systematic review looked at the quantification of cfDNA for predicting PE (Martin et 
al., 2014). The study included 3 prospective cohort studies and ten case-control studies with 
a total of 440 cases of PE and 2,576 controls. They found that in 11 of the 13 studies, 
significantly higher concentrations of fetal cfDNA were present in women who developed PE. 
However, in was noted that most of these studies did not adequately control for possible 
confounding factors such as BMI, smoking status and racial origin, and that the definitions of 
PE and its severity varied largely. As a result of this significant heterogeneity between the 
published studies, a clinically meaningful meta-analysis was not possible, and therefore no 
precise conclusions could be drawn. In a recent study, it was demonstrated that, at 11-13 
weeks of gestation, in pregnancies that subsequently develop early-PE, the median maternal 
plasma concentration of total cfDNA was increased and fetal fraction was reduced. In 
pregnancies that developed late-PE the median fetal fraction at 20–24 weeks was reduced. 
However, both total cfDNA and fetal fraction were affected by maternal characteristics and 
when these associations were taken into account, the MoMs in the PE cases were not 
significantly different from normotensive controls. Thus, a beneficial consequence of applying 
cfDNA in the screening for PE has yet to be proved for routine clinical practice (Rolnik et al., 
2015).  
1.4.5 Combined screening approach 
Effective first trimester screening for PE can also be achieved using a combination of maternal 
factors, and the above mentioned biochemical and biophysical markers, in a similar approach 
to that of the combined screening test for Down’s syndrome. A prospective screening study 
with 33,602 singleton pregnancies using a combined approach reported a prevalence of early 
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(<34 weeks), intermediate (34-37 weeks) and late PE (>37 weeks) to be 0.3%, 0.6% and 1.3%, 
respectively. This combined method of screening was performed using a logistic regression 
analysis to derive the a priori risk for each of the PE groups from maternal characteristics. The 
maternal factors-related a priori risks were then multiplied by the likelihood ratios of the 
biophysical and biochemical markers to derive the a posteriori risks and these were used to 
calculate the detection rates at fixed FPRs of 5 and 10%. Various algorithms which combined 
maternal characteristics with biophysical and biochemical tests at 11–13 weeks’ gestation 
identified approximately 90%, 80% and 60% of pregnancies that subsequently developed 
early, intermediate and late PE, at a FPR of 5% (Akolekar et al., 2011). 
1.4.6 Quality control of biomarkers 
The development of quality assurance and quality control systems in prenatal care has arisen 
as a result of the strive for excellence and self-improvement, the need to deliver the best 
possible care, and the increasing impact of legal aspects in obstetrics and ultrasound practice. 
Early advances in quality control originated from the nuchal translucency (NT) screening 
programme (Wojdemann et al., 2001; Snijders et al., 2002). This was a consequence of a large 
variation in screening efficiency between centres, illustrating that conditions under which the 
measurement is performed should be clearly defined. This approach led to both quantitative 
and qualitative forms of control. The quantitative approach compares the distribution of 
measurements taken with reference values (Snijders et al., 1998; Snijders et al., 2002). A 
qualitative control mechanism assesses an individual’s performance, through a process of 
audit. Such an audit involves both assessment of the distribution of measurements for a given 
sonographer as well as examination of the quality of random images from each sonographer. 
If the criteria are met, the sonographer may be given a certification of competence.  
There is particularly relevant in the context of screening for PE as each of the biochemical and 
biophysical markers are susceptible to inaccurate measurements, thus impacting on the risk 
given to the patient. The quality of the biomarkers can be assessed by close surveillance of 
their median MoMs using a cumulative sum (CUSUM) chart (Figure 1.7). The CUSUM chart 
allows detection of both increases and decreases in a process within parameter of interest. 
Deviations can be flagged up and addressed in a timely manner in order to avoid profound 
adverse inaccuracies in the screening system. Inaccurate biochemical marker results may 
occur as a result of a change in batch of reagent used, a change in temperature, deviation 





Figure 1.7 Example of a CUSUM plot. 
This chart plots the lowest uterine artery pulsatility index (L-PI) measurements of each 
sonographer over the course of a study. Sonographers whose measurements were not 
consistently within the 0.90–1.10-MoM control range are indicated by black lines (Taken from 
Ridding et al., 2015a). 
 
The biophysical markers MAP and uterine artery PI are equally susceptible to extensive 
variability in measurement. This results from poor adherence to a well-defined protocol. The 
quality control of the uterine artery Doppler PI has been shown to be more accurate in a group 
of sonographers who received feedback on their performance than those without any feedback 
(Ridding et al., 2015a). In addition, the researchers found that the screen positive rate was 
also significantly higher (4.3% vs 6.8%; p=0.012) in the no-feedback group.  
Other studies have demonstrated that measurements distal to the correct sampling site (Khalil 
and Nicolaides, 2013c) result in lower PI values (Lefevbre et al., 2012; Ridding et al., 2015b). 
Operators with a low central tendency (median MoM<0.95) may be sampling the uterine artery 
too distally in a significant proportion of patients. In contrast, for operators who tend to 
overestimate the MoM (>1.05), the measurement acquisition is unknown and although never 
formally tested, it is suspected that the uterine artery PI value is from a sampling site proximal 
to the recommended site.  
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1.5 Factors that may reduce the risk of preeclampsia 
Although there is no proven effective treatment or prevention for this multisystem disorder, the 
physician must make a decision in the best interests of both the mother and the fetus. The 
target is to prolong the pregnancy for as long as is safely possible, to minimise the adverse 
effects of fetal prematurity. In doing so, there is a risk of worsening of the maternal disease, 
which in turn could potentially compromise both mother and baby. There are several possible 
factors that have been investigated and used in order to try to prevent PE. These include 
various lifestyle measures, dietary supplementation and pharmacological treatment. 
1.5.1 Lifestyle measures 
Regular exercise in pregnancy, in addition to reducing long-term obesity, is perceived to have 
beneficial effects in reducing the risk of developing PE. This physical activity can also reduce 
markers of insulin resistance and endothelial dysfunction that are known to be elevated in PE. 
However, exercise could in theory, be associated with an increased risk of PE as it may be 
associated with increased oxidative stress (Osterdal et al., 2009), one of the above mentioned 
potential pathophysiological mechanisms of the disorder. Consequently, conflicting opinions 
are divided between health-care professionals on exercise during pregnancy. 
A study reported in 2003 retrospectively examined 201 women with PE and 383 women with 
normotensive patients (Sorensen et al., 2003). Women were given a structured questionnaire 
regarding the sort, duration, frequency and intensity of exercise both during pregnancy, and in 
the year preceding the pregnancy. The study reported an overall 35% reduced risk (95% CI 
0.43 to 0.99) of PE, corrected for age, BMI, parity, smoking and race, in women who exercised 
regularly in the first 20 weeks of pregnancy, compared to inactive women. The risk of PE was 
inversely related to the frequency and intensity of exercise. Interestingly, women who had 
undertaken regular exercise in the year preceding pregnancy had a similar risk reduction to 
those who exercised during pregnancy (Odds ratio (OR) 0.67, 95% CI 0.42 - 1.08). 
Another study evaluated the impact of exercise on the risk of preeclampsia. The authors 
distributed a questionnaire to pregnant women between the gestational weeks 14 and 22, and 
reported an overall reduction in risk of preeclampsia with exercise of 21% (95% CI 0.65 - 0.96). 
However, this effect was most marked in women with a normal BMI, and no beneficial effect 
of exercise was seen with pregnancy in those with a BMI >30 kg/m2. This led the authors to 
believe that the beneficial effects of exercise in pregnancy only applied to the non-obese 
population (Magnus et al., 2008).  
A review of the literature in this field led the American College of Obstetrics and Gynaecology 
(ACOG Committee Opinion, 2002) to recommend that in the absence of medical or obstetric 
complications, pregnant women should perform 30 minutes of moderate exercise daily. 
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Similarly, the NICE guidance was that starting or continuing a moderate course of exercise is 
not associated with adverse outcomes (Kenyon et al., 2007). A recent randomised control 
study with 765 patients divided women into two groups to assess whether exercise protects 
against hypertension and macrosomia. The group randomised to exercise trained 3 days per 
week for 50 to 55 minutes per session from 9-11 until 38-39 weeks’ gestation. The 85 training 
sessions involved aerobic exercise, muscular strength, and flexibility. The authors reported 
that high attendance to this programme, regardless of BMI, that pregnant women who did not 
exercise are 3 times more likely to develop hypertension (OR 2.96; 95% CI, 1.29-6.81, P=0.01) 
and are 1.5 times more likely to gain excessive weight (OR 1.47; 95% CI 1.06-2.03, P=0.02).  
In addition, the lack of exercise increases the risk 2.5 times to give birth to a macrosomic infant 
(OR 2.53; 95% CI 1.03-6.20, P=0.04) (Barakat et al., 2016). 
1.5.2 Calcium supplementation 
It has been suggested that calcium supplementation reduces high BP. Low calcium intake may 
elevate BP by stimulating either parathyroid hormone or renin release, which results in 
increased intracellular calcium in vascular smooth muscle causing vasoconstriction (Belizan 
et al., 1988). In 1952 it was reported that Ethiopian women, who had a diet rich in calcium, had 
a low prevalence of PE (Hamlin, 1952). In the calcium to prevent preeclampsia (CPEP) double 
blinded randomised control trial, 4589 healthy nulliparous women, at 13 to 21 weeks’ gestation, 
were randomised to either 2g of calcium daily or a placebo. There was no significant difference 
in rates of PE (6.9% vs 7.3% (RR 0.94; 95% CI 0.76-1.16)), gestational hypertension (77% vs 
76%, RR 1.04; 95% CI 0.74-1.38), preterm deliveries (10.8% vs 10%), or in perinatal mortality 
(34% vs 36%) in the calcium and placebo group respectively.  
A Cochrane database systematic review involving 14 studies that included 15,730 women 
reported that calcium supplementation of more than 1g per day was associated with a 
reduction in risk of PE (Relative risk (RR) 0.45, 95% CI 0.31-0.65), particularly for women with 
low-calcium diets (RR 0.36, 95% CI 0.20-0.65). The validity of these promising results, 
however, had limitations as the results could have been potentially confounded by the inclusion 
of several small trials with a high proportion of women with low dietary calcium intake. This is 
evident from the significant amount of heterogeneity between these studies (Hofmeyr et al., 
2014). It therefore remains uncertain whether calcium supplementation helps reduce the risk 
of PE. 
1.5.3 Anti-oxidants 
As oxidative stress has been associated with the pathophysiology of PE, there have been 
studies which have examined whether anti-oxidants administration would reduce the 
production of reactive oxygen species (ROS) and in turn, oxidative stress (Vaughan and 
55 
 
Walsh, 2002). This could in theory impact the development of PE. Anti-oxidants play a key role 
in maintaining cellular integrity in normal pregnancy. They do this by inhibiting peroxidation 
reactions which protects vital enzyme action, proteins and cells from destruction by peroxides 
(Rumbold et al., 2006). The studies that have investigated the role of anti-oxidants in the 
prevention of PE have mostly involved the use of vitamins C and E. The former, vitamin C 
(ascorbic acid) scavenges free radicals in the aqueous phase, and the lipid soluble vitamin E 
(-tocopherol) acts in vivo to prevent the formation of lipid peroxides and thereby, protects cell 
membranes (Rumbold et al., 2006). Diet supplementation of these vitamins may reduce the 
oxidative stress by preventing endothelial damage and the subsequent development of PE.  
A meta-analysis of seven studies that included 5,969 women, concluded that concomitant 
supplementation with vitamins C and E does not prevent PE in women at risk (pooled RR: 
0.79; 95% CI 0.58-1.08), but actually increases the rate of babies born with a low birth weight 
(pooled RR: 1.13; 95% CI of 1.00-1.27) (Rahmi et al., 2009). 
Magnesium supplementation in pregnancy has also been implicated as a possibility of 
reducing the incidence of PE (Conradt et al., 1984). Unfortunately, a Cochrane review of two 
randomised trials (474 patients) showed no apparent effect of magnesium treatment on the 
risk of PE or GH (Makrides and Crowther, 2001). 
Another anti-oxidant, which has been investigated in regard to prevention of PE is Zinc. It is 
an essential trace element important for many metabolic pathways. A reduction in maternal 
and umbilical plasma zinc concentrations has been seen in women with PE when compared 
to normal pregnancy (Bassiouni et al., 1979).  This is possibly due to the fact that zinc and 
oestrogen compete for common binding sites on plasma proteins (Adeniyi, 1987). These 
findings led to a recommended maintenance of adequate dietary zinc nutrition during 
pregnancy. Two randomised controlled trials involving 1,288 patients, however, failed to 
demonstrate any significant benefit (Mahomed et al., 1989; Jonsson et al., 1996). 
1.5.4 Folate 
There are both animal and human studies which promote the role of folic acid in the prevention 
of PE (Wen et al., 2008a and 2008b). The mechanisms to explain this effect include a 
contribution to placental growth and development, by lowering blood homocysteine levels and, 
through the effect of folic acid in improving endothelial function. 
Hyperhomocysteinemia is a risk factor for PE and by reducing plasma levels of homocysteine 
with folic acid, it is hypothesised that this may reduce the risk of PE (Lindblad et al.,2005; 
Guven et al., 2009). Increased levels of homocysteine also can lead to endothelial activation 
and folic acid may mitigate this endothelial dysfunction thereby contributing to the prevention 
of PE (Powers et al., 1998). 
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There is data from four retrospective cohort studies which examined the effect of folic acid in 
the prevention of PE which suggest that regular use of folic acid supplementation reduces the 
risk of PE (Hernandez-Diaz et al., 2002; Bodnar et al., 2006; Wen et al., 2008a; Catov et al., 
2009). There are two other subsequent studies which failed to illustrate a protective effect of 
folic acid supplementation (Timmermans et al., 2011; Li et al., 2013). A systematic review 
brought these studies together to find an OR of 0.14 (95% CI 0.06-0.31) for a reduction in risk 
of PE, showing a strong protective effect of folic acid supplementation (Wen et al., 2013).  
There is currently an international multicentre RCT in progress to examine the effectiveness 
of folic acid in the prevention of PE. This study, ‘The Effect of Folic Acid Supplementation in 
Pregnancy on Preeclampsia: the Folic Acid Clinical Trial (FACT) aims to recruit 3,656 high risk 
women to evaluate whether supplementation of folic acid throughout pregnancy will impact the 
development of PE. Those patients categorised into the high-risk group will be randomised in 
a 1:1 ratio to either folic acid 4.0 mg or placebo between 8 and 16 weeks of gestation will (Wen 
et al., 2013). 
1.5.5 Heparin 
As discussed above, the placenta in pregnancies affected with PE are associated with 
thrombosis, necrosis and infarction. Consequently, it has been postulated that heparin, which 
is a large complex macromolecule, could be used to mitigate these pathological changes and 
potentially prevent development of the disorder. There has been much interest in investigating 
the use of low molecular weight heparin (LMWH) alone or in combination with an anti-platelet 
drug for prevention of miscarriage, PE, and intrauterine growth restriction (IUGR) in pregnancy, 
especially in women with a known thrombophilic tendency or a previous history of PE. 
However, there are studies that have been too small and underpowered for reliable 
conclusions (Duley et al., 2006a; 2006b; Walker et al., 2006).  
Conversely, two systematic reviews summarising the published literature concluded that 
heparin does significantly reduce the recurrence of PE and is associated with reductions in 
perinatal mortality, preterm delivery, and growth restriction (<10th percentile) in high-risk 
women (Dodd et al., 2013; Rodger et al., 2014). Roberge et al. (2015) reported in their meta-
analysis that there is some evidence that using LMWH with aspirin in women with a history of 
PE compared to aspirin alone was associated with a significant reduction in PE (RR 0.54, 95% 
CI 0.31-0.92) (Roberge et al., 2015). However, LMWH used alone vs no treatment was 
evaluated in a study of 135 participants and did not a signiﬁcant reduction in adverse perinatal 
outcome (risk difference, 2.2 (95% CI 11.6-16.0); P = 0.76 (Martinelli et al., 2012). Similarly, 
the TIPPS trial including 292 women showed that LMWH without aspirin had no effect on 
adverse outcome (Rodger et al., 2014). 
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The exact mechanism of action of LMWH and how it potentially prevents PE remains elusive 
but it is likely to be attributable to the anti-coagulant action of heparin within the placenta. 
Another hypothesis is that LMWH could exert a direct vascular action in the maternal 
compartment to reverse the placenta-mediated systemic vascular dysfunction characteristic of 
PE (McLaughlin et al., 2015). It has also been shown that LMWH can significantly reduce 
systolic and diastolic blood pressure and can reduce vascular resistance in the utero placental 
circulation (Mello et al., 2005). Although, there is some evidence for a its potential role in 
preventing PE in high-risk women, large high quality RCTs are necessary to corroborate the 
results of smaller studies and to define the extent of any possible benefit in reducing the 
prevalence of PE. 
1.5.6 Aspirin 
Research into the use of low-dose aspirin (acetylsalicylic acid) for the prevention of PE has 
been ongoing for the last 30 years. Crandon and Isherwood (1979) observed that nulliparous 
women who had taken aspirin regularly during pregnancy were less likely to have PE than 
those who did not. Aspirin exerts its effect by targeting prostaglandin pathways and modifying 
the imbalance between thromboxane A2 and prostacyclin, which is altered in PE and 
contributes to the vasospasm and coagulation abnormalities. In normal pregnancy, 
prostacyclin concentrations increase and cause a reduction in systemic vascular resistance by 
reducing the maternal response to angiotensin II and other vasopressors (Wallenburg et al., 
1991). In PE, the ratio of thromboxane A2 to prostacyclin is disrupted as, eicosanoid synthesis 
is greatly altered with relatively low prostacyclin levels. This imbalance leads to the 
augmentation of the pressor effects of angiotensin II and catecholamines, resulting in the 
clinical syndrome of PE (Chavarria et al., 2003). 
Low-dose aspirin treatment in pregnancy is thought to prevent the development of PE by 
inhibiting the biosynthesis of placental thromboxane A2 with minimal effects on vascular 
prostacyclin levels (Sibai et al., 2005). The enzyme cyclo-oxygenase (COX) plays a pivotal 
role in the production of both prostacyclin and thromboxane A2. Aspirin inhibits endothelial 
cyclo-oxygenase (Dekker and Sibai, 2001) and this process is irreversible in platelets, where 
the enzyme is inhibited for their entire life-span. In contrast, when the enzyme is re-synthesised 
in endothelial cells, the prostacyclin production is re-established relatively rapidly. This 
selective inhibition of cyclo-oxygenase and the resulting alteration in the prostacyclin to 
thromboxane A2 ratio in the placenta, forms the basis of using aspirin to prevent or delay the 
onset of PE. 
In the wake of Crandon and Isherwood’s study, more reports emerged in the literature 
suggesting that low dose aspirin in high-risk women reduces the prevalence of fetal growth 
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restriction and PE (Beaufils et al., 1985; Wallenburg et al., 1986). Following this, there were a 
number of large randomised studies that showed aspirin had no effect on PE (Italian Study of 
Aspirin in Pregnancy, 1993; CLASP Collaborative Group, 1994). It is believed that the negative 
outcome of these studies was due to the low risk population selection. 
A subsequent meta-analysis, which examined more than 30,000 women from 39 trials, 
reported that the use of an anti-platelet agent was associated with a 15% reduction in the risk 
of PE (32 trials; 29,331 women; pooled RR 0.85) with an 8% reduction in the risk of preterm 
birth before 37 weeks and a 14% reduction in the risk of fetal or neonatal death in women 
allocated to low dose aspirin (Duley et al., 2001). The PARIS (Perinatal Antiplatelet Review of 
International Studies) collaborative group (2005) examined individual patient data from 32,217 
women from 31 randomised trials of antiplatelets for the prevention of PE. They found that 
women assigned to receive anti-platelet treatment, had a relative risk (RR) of developing PE, 
of delivering before 34 weeks and of having a pregnancy with a serious adverse outcome of 
0.90. Their findings were similar to those of Duley et al. (2004) in that there was a moderate 
but consistent reduction in the relative risk of PE (Askie et al., 2007). 
A number of randomised studies have examined the value of prophylactic aspirin in women 
with increased impedance to flow in the uterine arteries. A meta-analysis examining nine of 
these studies, with a total of 1,317 women, assessed the influence of gestational age at the 
time of administration of low dose aspirin on the incidence of PE. These women were 
categorised as high risk, based on an abnormal uterine artery Doppler ultrasound. This study 
showed that aspirin treatment commenced in early gestation was, in fact, associated with a 
greater reduction in the incidence of PE than treatment started in late gestation: <16 weeks of 
gestation resulted in a RR of 0.48 (95% CI 0.33-0.68), at 17-19 weeks RR 0.55 (95% CI 0.17-
1.76), and at > 20 weeks RR 0.82 (95% CI 0.62-1.09) (Bujold et al., 2009). The same group 
performed another meta-analysis with 11,348 patients and found again in 9 RCTs with 764 
patients, that aspirin prescribed prior to 16 weeks’ gestation was significantly associated with 
a reduction in PE (RR 0.47, 95% CI 0.34-0.65) and IUGR (RR0.44, 95% CI 0.3-0.65). Aspirin 
started after 16 weeks’ gestation in 18 RCTs with 10,584 women, was not associated with a 
reduction in the incidence of PE or IUGR (RR 0.81 95% CI 0.63-1.03 and RR 0.98, 95% CI 
0.87-1.1 respectively) (Bujold et al., 2010). 
The authors subsequently examined the effect of early administration of aspirin from 5 studies 
with 556 patients and reported that it was particularly effective in preventing early PE requiring 
delivery before 37 weeks’ gestation, rather than at term (RR 0.11, 95% CI 0.04-0.33 vs RR 
0.98, 95% CI 0.42-2.33) (Roberge et al., 2012a). In another meta-analysis, 4 studies with 392 
women, severe PE, as opposed to mild PE was significantly decreased with aspirin given prior 
59 
 
to 16 weeks’ gestation (RR 0.22, 95% CI 0.08-0.57 vs RR 0.81, 95% CI 0.33-1.96, respectively) 
(Roberge et al., 2012b). Additionally, they highlighted there was also a 50% reduction in the 
risk of IUGR and 60% reduction in the risk of perinatal death if treatment was commenced 
before 16 weeks rather than there after (Roberge et al., 2013; Bujold et al., 2014). 
More recently, a retrospective analysis of two cohorts who screened high risk for PE in the first 
trimester, showed a significant reduction in the incidence of both early and late PE in the cohort 
of women prescribed 150mg of aspirin following screening (p<0.01 and p=0.03, respectively) 
(Park et al., 2015). It has been widely postulated that aspirin’s mechanism of action particularly 
benefits those who are at high risk of early PE as a consequence of improved placentation. 
However, a triple blinded randomised control trial which gave either 150mg of aspirin or a 
placebo to patients with abnormal uterine artery Dopplers in the first trimester, found no 
difference in the mean uterine artery PI at 28 weeks’ gestation. The only true way to answer 
the question as to whether aspirin prevents PE is to conduct an adequately powered double 
blinded randomised control trial which following an effective first trimester screening 




CHAPTER 2 PATIENTS AND METHODS 
 
2.1 Study population 
The first study, the development of the competing risks model, presented in chapter 3 is based 
on data collected from two UK hospitals as a part of the prospective screening study for 
hypertensive disorders.  The second and third studies in chapter 3, the validation study and 
the comparison study, are based on data collected from 12 maternity hospitals in five different 
EU countries, as part of a prospective first trimester screening quality study for preeclampsia. 
 
2.1.1 The competing risks model 
This study was a part of an ongoing prospective screening study for early prediction of 
pregnancy complications in women attending their first routine hospital visit in pregnancy at 
King’s College Hospital, London, and Medway Maritime Hospital, Gillingham, between 
February 2010 and July 2014. 
 
At this appointment, which is held between 11+0 and 13+6 weeks’ gestation, all women have an 
ultrasound scan to confirm the gestational age using the measurement of the fetal crown rump 
length (CRL), to diagnose the presence of any major fetal abnormalities and to measure fetal 
nuchal translucency (NT) thickness and maternal serum free β-human chorionic 
gonadotrophin (b-hCG) and PAPP-A as part of screening for chromosomal abnormalities 
(Snijders et al., 1998; Kagan et al., 2008b). 
 
All women attending for this visit were invited to participate in the research study entitled ‘Early 
Prediction of Pregnancy Complications’. Written informed consent was obtained from those 
agreeing to participate in the study. We subsequently recorded maternal characteristics and 
medical and obstetric history, measured the uterine artery pulsatility index (PI) by 
transabdominal colour Doppler, mean arterial pressure (MAP) (section 2.4) using a validated 
automated device and stored plasma and serum at -80oC for subsequent biochemical analysis. 
 
The inclusion criteria for this study were singleton pregnancies delivering a phenotypically 
normal live birth or stillbirth at or after 24 weeks’ gestation. We excluded pregnancies with 














Maternal age in years, median (IQR) 31.5 (27.0, 35.6) 31.3 (26.8, 35.0) 0.34501 
Maternal weight in kg, median (IQR) 72.1 63.0, 86.7) 66.5 (59.0, 77.0) 0.37555 
Maternal height in cm, median (IQR) 163.2 (159, 168) 164.5 (160, 169) 0.19445 
Body mass index, median (IQR) 27.1 (23.5, 32.1) 24.5 (21.9, 28.3) 0.66575 
Gestational age in weeks, median (IQR) 12·6 (12·3, 13·0) 12·7 (12·3, 13·1) 0.19424 
Racial origin   <0.0001 
  Caucasian, n (%) 564 53.3%) 25,315(72.6%)  
  Afro-Caribbean, n (%) 394 (37.2%) 6,287 (18%)  
  South Asian, n (%) 56 (5.3%) 1,567 (4.5%)  
  East Asian, n (%) 17 (1.6%) 829 (2.4%)  
  Mixed, n (%) 27 (2.6%) 892 (2.6%)  
Medical history    
  Chronic hypertension 140 (13.2%) 421 (1.2%) <0.0001 
  Diabetes mellitus 22 (2.1%) 303 (0.9%) 0·0008 
  SLE/APS 5 (0.5%) 48 (0.1%) 0.01679 
Cigarette smokers, n (%) 68 (6.4%) 3,195 (9.2%) 0.00278 
Family history of preeclampsia, (n, %)    
Parity   <0.0001 
  Nulliparous, n (%) 622 (58.8%) 16,739 (48%)  
  Parous with no previous PE, n (%) 283 (26.8%) 17,028 (48.8%)  
  Parous with previous PE, n (%) 153 (14.5%) 1,123 (3.2%)  
 
IQR = interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholopid syndrome  
Comparisons between outcome groups were by chi-square or Fisher exact test for categorical variables and Mann Whitney-U test 
for continuous variables; * significance value p<0.05 
 
In this screening study, the competing risks model, described in Chapter 3, we screened 
35,948 women with 1,058 (2.9%) cases that developed PE and 34,890 that were unaffected 
by PE. All women had a complete history taken with the biomarkers MAP, uterine artery PI, 
PAPP-A, and PlGF. In the PE group, compared to unaffected pregnancies, there was no 
significant difference in maternal age, weight, and BMI. There was, however, a higher mean 
prevalence of Afro-Caribbean racial origin, family and previous history of PE, chronic 
hypertension, diabetes mellitus and systemic lupus erythematosus or antiphospholipid 




2.1.2 The validation study 
This was a prospective, non-interventional, multicentre validation study of the competing risks 
model (described above in section 2.1.1) in screening for preeclampsia by maternal factors 
and biomarkers at 11-13 weeks’ gestation. The study was comprised of singleton pregnancies 
at 11+0 -13+6 weeks’ gestation in women booking for routine pregnancy care at the following 
hospitals; King’s College Hospital, London, UK, Medway Maritime Hospital, Gillingham, UK, 
Homerton University Hospital, London, UK, North Middlesex University Hospital, London, UK, 
Southend University Hospital, Essex, UK, Lewisham University Hospital, London, UK, Hospital 
Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, Hospital Universitario San Cecilio, 
Granada, Spain, Hospiten Sur, Tenerife, Spain, Centre Hospitalier Universitaire Brugmann, 
Brussels Belgium, Attikon University Hospital, Athens, Greece and Ospedale Maggiore 
Policlinico, Milan, Italy.  
 
All women undergoing routine screening for aneuploidies in these hospitals were invited to 
participate in the screening study for preeclampsia. In women who agreed to participate in the 
study, the maternal MAP was measured by automated devices (Poon et al., 2012), and 
transabdominal colour Doppler ultrasound was used to visualise the left and right uterine 
artery, to measure the PI in each vessel and calculate the mean PI (Plasencia et al., 2007). 
Maternal serum samples were taken via standard venepuncture for the analysis of PAPP-A 
and PlGF using a Delfia Xpress automated machine. 
 
The patients who attended for their first trimester ultrasound between 11-13 weeks’ gestation 
were recruited between February and September 2015 and gave written informed consent to 
participate in the study, which was approved by the NHS Research Ethics Committee in the 
UK and the Ethics Committee of each participating hospital in other countries. 
 
The inclusion criteria for this study required patients to be aged 18 years or more, singleton 
pregnancy, and have a live fetus at the time of screening. Those with multiple pregnancies, 
major abnormalities identified at the ultrasound scan, those deemed to lack capacity to be able 
to consent to participate, and pregnancies ending in termination or miscarriage, were excluded 
from the study. 
 
During the study period, 9,041 pregnancies meeting the inclusion criteria underwent screening 
for PE. The maternal demographics can be seen in table 2.2. We subsequently excluded 266 
(2.9%) cases because they had a major fetal defect (n=33), the pregnancy resulted in 




In the PE affected group, compared to unaffected pregnancies, there was no significant 
difference in maternal age, smoking status and systemic lupus erythematosus or 
antiphospholipid syndrome. As in the competing risks model, we did observe a higher 
prevalence of Afro-Caribbean racial origin, those with a family and personal history of PE, 
chronic hypertension, diabetes mellitus and a lower prevalence of cigarette smokers. 
 
2.1.3 The comparison study 
This study used the data obtained from the above prospective validation study to directly 
compare the detection rates of preeclampsia using our competing risks model with the 
screening strategies recommended by the National Institute of Health and Clinical Excellence 
(NICE, 2010) and the American College of Obstetricians and Gynecologists (ACOG, 2015).  
2.2 Recording of information 
Prior to seeing a doctor, women were asked to complete a questionnaire on age, racial origin 
(Caucasian, African, South Asian, East Asian and Mixed), cigarette smoking during pregnancy 
(yes or no), method of conception (spontaneous or assisted conception by either ovulation 
induction alone or in vitro fertilisation), medical history (including chronic hypertension, 
diabetes mellitus, anti-phospholipid syndrome, thrombophilia and sickle cell disease), 
medication (including anti-hypertensive, anti-depressant, anti-epileptic, aspirin, steroids, 
betamimetic, insulin, and thyroxine), parity (parous, nulliparous with no previous pregnancies, 
nulliparous with miscarriage or termination before 24 weeks), previous pregnancy with PE (yes 
or no) and family history of PE (mother, sister or both). The questionnaire was then reviewed 
by a doctor and the medical and obstetric history was recorded on an electronic database. 
 
The following measurements were taken: 
• Maternal weight and height were measured and the BMI was calculated in Kg/m2, 
• Stabilised measurement of systolic BP, diastolic BP and MAP, 
• Uterine artery PI of the two arteries, 
• Measurement of maternal serum PAPP-A and PlGF concentrations. 
2.3 Ethical committee approval 
The screening study which resulted in the competing risks model was a sub study of the Early 
Prediction of Pregnancy Complications Study, which was approved by the King’s College 
Hospital Ethics Committee (Ref: 02-03-033, R&D reference number 03WH06). The patients 
received an information leaflet outlining the details of the research study (appendix 1) and 




The prospective validation and comparison study was part of an FP7 EU funded study entitled 
Combined Multi-Marker Screening and Randomised Patient Treatment with Aspirin for 
Evidence-based Pre-eclampsia (ASPRE). A favourable opinion was granted by the National 
Research Ethics Service (NRES) Committee London – Fulham (Ref 13/LO/1479). As with the 
screening study above, the potential participants received a patient information sheet 
(appendix 3) providing an overview of the study and those that agreed to partake in the 
research, signed a consent form (appendix 4) agreeing to the terms and conditions of the 
study. 
 
2.4 Biochemical markers 
Patient blood samples were collected for all patients who provided written consent agreeing to 
take part in the research. The blood samples were collected in two 10ml tubes [red (plain) and 
purple (EDTA)]. The tubes were labelled with a patient identifying barcode and transferred to 
the laboratory. The samples were processed in the laboratory after a standing time of 10-15 
minutes at room temperature to allow for clotting. The samples were centrifuged at 3000rpm 
for 10 minutes to separate serum and plasma. 0.5ml of the serum was separated into a falcon 
and placed in the DELFIA® Xpress (DX) analyser for the biochemistry results. 
 
2.4.1 Pregnancy associated plasma protein-A 
Maternal serum pregnancy associated plasma protein-A (PAPP-A) was measured using a 
DELFIA® XPRESS analyzer (PerkinElmer Life and Analytical Sciences, Waltham, USA). This 
is solid-phase, two-site fluoroimmunometric assay that is based on the indirect sandwich 
technique. The assay utilises monoclonal antibodies immobilised on microplates which are 
directed against the PAPP-A protein. During the elution process, PAPP-A binds to the coated 
wells and interacts with europium tagged monoclonal antibodies. The addition of an 
enhancement solution causes dissociation of the tag from the antibody where they form highly 
fluorescent chelates with components of the enhancement solution. The fluorescence is 
proportional to the concentration of PAPP-A in the sample and its concentration can be 
measured. The measured maternal serum PAPP-A was converted to multiples of the expected 
normal median (MoM) corrected for fetal CRL, maternal age, weight, smoking, parity, racial 
origin and method of conception as previously described (Kagan et al.,2008a). 
 
2.4.2 Placental growth factor 
The assay used for the competing risk model was the DELFIA® Xpress PlGF assay. This is a 
solid phase, two-site fluoroimmunometric assay in which monoclonal antibodies (derived from 
mice) and polyclonal antibodies (derived from rabbits) are directed against the PlGF molecule 
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and is based on the direct sandwich technique. Patient blood samples, containing PlGF, are 
reacted with immobilised polyclonal antibodies directed against the PlGF. Europium-labelled 
monoclonal antibodies directed against an antigenic site on the PlGF are reacted with the PlGF 
bound to the solid-phase antibody. DELFIA® Inducer dissociates europium ions from the 
labelled antibodies in the sample, where they form highly fluorescent chelates with 
components of the DELFIA® Inducer. The fluorescence in each cup is then measured. The 
europium fluorescence from each sample is proportional to the concentration of PlGF in the 
sample. 
The DELFIA® Xpress PlGF 1-2-3 assay was used for the validation and comparison studies. 
This is a newer assay with the main difference being that it uses two monoclonal antibodies. 
The second monoclonal antibody attaches to the PlGF with the europium tag and its 
fluorescence can be measured to produce a PlGF concentration. The measured maternal 
serum PlGF was converted to multiples of the expected normal median (MoM) corrected for 





Table 2.2 Maternal and pregnancy characteristics in the validation and comparison study 
 
IQR = interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome; Comparisons between 
outcome groups were by chi-square or Fisher exact test for categorical variables and Mann Whitney-U test for continuous variables 
 
2.5 Biophysical markers 
 
2.5.1 Blood pressure 
The blood pressure (BP) was taken by validated automated devices (Microlife Watch BP 
Home, Taipei, Taiwan; Chung, 2009) that were calibrated before and at regular intervals during 
the study (every 1,000 inflations). The recordings were made by doctors or midwives or 
researchers who had received appropriate training on the use of these machines. Women were 
allowed to rest for 5-10 minutes and the BP measurements were taken in a quiet room with 
 Maternal characteristics 
Delivery with preeclampsia 
None (n=8,536) <32 (n=17) <37 (n=59) >37 (n=180) 
Maternal age in years, median (IQR) 31.5 (27.3, 35.0) 29.8 (26.7, 34.6) 30.6 (25.95, 34.7) 31.2 (27.8, 34.8) 
Maternal weight in Kg, median (IQR) 66.2 (58.8, 76.9) 72.6 (65.6, 86.0) 69.8 (63.0, 87.8) 75.0 (64.9, 84.0) 
Maternal height in cm, median (IQR) 165 (160, 169) 164 (161, 166) 164 (160, 169) 164 (159, 168) 
Body mass index, median (IQR) 24.5 (21.9, 28.3) 27.3 (23.9, 31.8) 27.1 (23.6, 31.82) 27.8 (23.9, 31.5) 
Gestational age in weeks, median (IQR) 12.7 (12.3, 13.1) 12.6 (12.3, 12.7) 12.7 (12.4, 13.0) 12.7 (12.3, 13.2) 
Racial origin, n (%)       
  Caucasian 6,716 (78.7) 8 (47.1) 38 (64.4) 129 (71.7) 
  AfroCaribbean 1,040 (12.2) 8 (47.1) 14 (23.7) 36 (20.0) 
  East Asian 153 (1.8) 0 (0.0) 0 (0.0) 1 (0.6) 
  South Asian 447 (5.2) 0 (0.0) 3 (5.1) 12 (6.7) 
  Mixed 180 (2.1) 1 (5.9) 4 (6.8) 2 (1.1) 
Medical history, n (%)       
  Chronic hypertension 75 (0.9) 3 (17.7) 9 (15.3) 16 (8.9) 
  Diabetes mellitus 63 (0.7) 2 (11.8) 3 (5.1) 2 (1.1) 
  SLE or APS 32 (0.4) 0 (0.0) 0 (0.0) 0 (0.0) 
Cigarette smoking, n (%)   717 (8.4) 1 (5.9) 4 (6.8) 11 (6.1) 
Family history of preeclampsia, n (%)   434 (5.1) 1 (5.9) 7 (11.9) 17 (9.4) 
Conception, n (%)       
  Spontaneous 8,254 (96.7) 17 (100) 57 (96.6) 173 (96.1) 
  In vitro fertilization 218 (2.6) 0 (0.0) 2 (3.4) 7 (3.9) 
  Ovulation drugs 64 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Parity, n (%)       
  Nulliparous 3,972 (46.5) 11 (64.7) 36 (61.0) 119 (66.1) 
  Parous: no previous preeclampsia 4,396 (51.5) 4 (23.5) 17 (28.8) 46 (25.6) 
  Parous: previous preeclampsia 168 (2.0) 2 (11.8) 6 (10.2) 15 (8.3) 
Pregnancy interval in years, median 
(IQR) 2.7 (1.6, 4.6) 5.4 (4.3, 7.2) 4.1 (2.4, 6.8) 3.4 (2.0, 5.4) 
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temperature of between 20°C and 24°C. The women were seated, with their arms supported 
at the level of the heart and either a small (< 22cm), normal (22-32 cm) or large (33-42 cm) 
adult cuff was used depending on their mid arm circumference (Pickering et al., 2005; Poon et 
al., 2012). The BP was measured in both arms simultaneously (Figure 2.1) and 2 recordings 
of BP were taken and the MAP was calculated using an average of the two systolic and 
diastolic readings. A patient with BP above 140/90mmHg was referred to the antenatal clinic 
for obstetric management as per the local protocol.  
 
 
Figure 2.1 Simultaneous measurement of blood pressure in both arms 
2.5.2 Uterine artery Doppler 
The measurement of uterine artery PI by transabdominal ultrasound required obtaining a 
sagittal section of the uterus and the visualisation of both the cervical canal and the internal 
cervical os. The transducer was then gently tilted from side to side and colour flow mapping 
was used to identify each uterine artery along the side of the cervix and uterus at the level of 
the internal os (Figure 2.2; Plasencia et al., 2007). Pulsed wave Doppler was used with the 
sampling gate set at 2 mm to cover the whole vessel and care was taken to ensure that the 
angle of insonation was less than 30o. When three similar consecutive waveforms were 
obtained, the uterine artery PI was measured from the left and right arteries (Figure 2.3). All 
sonographers obtained the Fetal Medicine Foundation Certificate of competence in obstetric 
Doppler imaging prior to their involvement in the study (http://www.fetalmedicine.com).The 
results of the Doppler studies were not given to the women or their doctors and did not 





Figure 2.2 The uterine artery as demonstrated by colour flow mapping along the side 
of the cervix and uterus at the level of the internal os. 
 
 
Figure 2.3 First trimester uterine artery waveform 
 
2.6 Outcome measures 
The definitions used for PE and GH were those of the International Society for the Study of 
Hypertension in Pregnancy (Davey and MacGillivray, 1988). In GH the diastolic BP should be 
90 mmHg or more on at least two occasions four hours apart from 20 weeks’ gestation in 
previously normotensive women in the absence of significant proteinuria. A diagnosis of PE 
was made if there was GH with proteinuria of 300 mg or more in a given 24 hour period or two 
readings of at least ++ on dipstick analysis of midstream or catheter urine specimens (if no 24-
hour collection was available). In PE superimposed on chronic hypertension significant 
proteinuria (as defined above) should develop after 20 weeks’ gestation in women with known 
chronic hypertension (ie a history of hypertension before conception or the presence of 




The obstetric medical records of all women with pre-existing or pregnancy associated 
hypertension were examined to differentiate definitively whether the condition was chronic 
hypertension, PE or GH.  
2.7 Statistical analysis 
2.7.1 The competing risks model 
This first trimester screening model for PE is based on a survival time model for the time of 
delivery for PE. Bayes theorem was used to combine maternal demographic and past medical 
history in formation with biochemical and biophysical markers that were converted into multiple 
of the median (MoM) values. We used the competing risks model described by (Kalbfleisch 
and Prentice, 2002). In this model, it is assumed that if the pregnancy was to continue 
indefinitely all women would develop PE. Therefore, there is a competition between the 
delivery with PE and delivery for other reasons (Figure 2.4). The model was applied to 
represent the distribution of gestational age at delivery with PE. In pregnancies at low risk of 
PE, the gestational age distribution is shifted to the right which implies that actually most 
pregnancies will deliver before the onset of PE. Conversely, in those at high risk of developing 
PE, the gestational age distribution at which they will develop PE is shifted to the left yielding 
a greater area under the curve before 42 weeks’ gestation with the implication that an 




Figure 2.4 The Competing risks model (taken from Wright et al., 2015). 
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The distribution of gestational age at delivery with PE was obtained by applying Bayes theorem 
to combine the prior distribution based on maternal characteristics with likelihoods of the time 
to delivery with PE given the biophysical and biochemical marker MoM values as above. 
Although such model fitting was complicated because of the censoring in situations when 
delivery occurred before PE, fitting regression models to censored data was carried out 
routinely with standard statistical software. For example, a delivery without PE at 37 weeks’ 
gestation would be classed as a censored observation, meaning that the PE event occurred 
after 37 weeks’ gestation. A delivery with PE at 37 weeks’ gestation is an observation at 37 
weeks’ gestation that is not censored. In the analysis, the outcome data for each individual 
comprises of a gestation at delivery and a variable indicating whether delivery was with or 
without PE.   
 
The values of uterine artery PI, MAP, PAPP-A and PLGF were log10 transformed to achieve 
homogeneity of variants and approximate Gaussian distributions around the mean. Each 
measured value in the unaffected and PE pregnancies was expressed as a MoM after 
adjusting for confounding characteristics (Wright et al., 2010 and 2012; Pandya et al., 2012). 
In each case of PE, the measurements were converted into a MoM and regression analysis 
was used to determine the relationship between log10 MoM values with gestational age at 
delivery. 
 
In the estimation of performance of screening the values of uterine artery PI, MAP, PAPP-A 
and PLGF in the whole screened population were simulated based on the mean and SD of the 
log10 transformed marker values in the unaffected and PE pregnancies. In the PE group the 
mean and SD values used for simulation were specific for each gestational week at delivery, 
which were estimated from the regression analysis of the log10 MoM values of available data 
with gestational age at delivery. 
 
2.7.2 The validation and comparison studies 
The previously described competing risks model algorithm above was used for calculation of 
patient-specific risk of delivery with PE <32, <37 and ≥37 weeks’ gestation in the 8,775 patients 
in the validation study. The pre-specified analyses for performance of screening by maternal 
factors and any combinations of maternal factors with MAP, uterine artery PI, PAPP-A and 
PlGF were estimation of areas under the receiver–operating characteristics curve (AUROC) 
and detection rates (DR), with 95% CI, at false positive rates (FPR) of 5% and 10%. The 
essential difference between the above competing risk model and the validation study is that 
the testing of the competing risks model was performed on the data set used to develop the 
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model. To test the model a five-fold cross validation was used in which the data set was 
randomly divided into one fifths and the data in each fifth was fitted into the model of the other 
4/5. This approach was taken to limit the degree of optimistic bias. The validation study used 
a new data set to prospectively validate the competing risk model. McNemar’s test was used 
for the comparison study to compare the screen positive rates in our data set between the 
competing risks model and the screening approach recommended by NICE and ACOG. The 
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CHAPTER 4 DISCUSSION & CONCLUSION 
_________________________________________________________________________ 
4.1 Development of the competing risks model 
The competing risks model is a new approach for early screening for PE achieved by 
combining the prior risk, derived from the maternal demographics and medical history, with the 
biophysical markers uterine artery PI and MAP and the biochemical markers PAPP-A and 
PlGF. In this survival time model, the gestation at the time of delivery for PE is treated as a 
continuous rather than a categorical variable. This approach has the advantage of facilitating 
the creation a more efficient screening model, as opposed to using separate models for early 
and/or late PE. To further strengthen this argument, our data support this hypothesis and 
model as the distribution of the MoMs of the above markers is linear with gestational age in 
pregnancies with PE. One such theory could be that PE is a single pathophysiological disorder 
with a wide spectrum of severity manifested in gestational age at which delivery becomes 
necessary for maternal and or fetal indications. In this way, the more severe the disease, i.e. 
the earlier delivery is required, the worse the MoMs are at 11-13 weeks’ gestation. 
 
In this study, there were 1,058 cases of PE with an overall incidence of 2.9%, which is 
consistent with the incidence quoted in the literature (WHO, 2005; Knight et al., 2014).  27.6% 
of these cases required delivery before 37 weeks’ gestation resulting in an incidence of preterm 
PE of 0.8%. All of the biomarkers showed a larger separation from the norm in cases of early 
PE than in those that occurred at later gestations. This observation is reflected in their detection 
of early rather than in late disease. This is in keeping with the ‘broken stick’ statistical model. 
The regression slopes of the biomarkers tend toward a normal MoM with time (advancing 
gestational age) but for most cases in reality, this is not observed as the woman will have 
delivered before this occurs. However, the regression lines for the log10 MoMs values of the 
uterine artery PI and PAPP-A intersect 1 when delivery occurs close to term and consequently 
show little or no discriminatory power between affected and unaffected cases beyond 40 
weeks’ gestation.  
 
The performance of each biomarker in combination with maternal factors was superior to that 
of screening by maternal factors alone (See chapter 3, page 78, table 4). PlGF combined with 
maternal characteristics gave the best DR of all the biomarkers and PAPP-A made the least 
contribution. However, by combining 2 or more biomarkers, better detection rates were 
achieved than by using individual biomarkers, with the exception of PAPP-A. This biomarker 
did not provide any significant improvement of detection rates (DR) when combined with PlGF, 
presumably due to the fact that they are both markers of placental inefficiency so there is a 
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considerable overlap in their ability to detect PE.  In screening for PE requiring delivery before 
37 weeks’ gestation the detection rate, at a 10% FPR, was 49% by maternal characteristics 
and with the addition of the biomarkers, this increased to 75%. The detection rate for PE 
requiring delivery after 37 weeks’ gestation was 47% with a FPR of 10%. 
 
Similar to screening for Down’s syndrome, the FPR and DR of PE are influenced by the 
characteristics of the study population and for a given risk cut-off, they are both higher in 
nulliparous than in parous women and in those of Afro-Caribbean compared with Caucasian 
racial origin. Consequently, comparison of the performance of screening using these 
algorithms between studies requires the appropriate adjustments for the characteristics of the 
population under investigation. 
 
4.2 The validation study 
Having established a working model, the subsequent study validated this model in 12 different 
hospitals across Europe. This prospective multicentre validation study demonstrated not only, 
that implementing an international first trimester screening programme was feasible, but also 
showed that the performance of such a programme was comparable to that of our original 
model. At a FPR of 10%, the prospective DRs of screening for PE using maternal factors, 
uterine artery PI, MAP, and PlGF were 100%, 75%, and 47% for PE requiring delivery before 
32, 37, and after 37 weeks’ gestation respectively. These findings confirm that first trimester 
screening for PE identifies a high proportion of cases that will develop early onset disease but 
the detection of term PE still remains a challenge. 
4.3 The comparison study 
The current recommended approach to screening for PE is based on using maternal 
demographics and medical history to identify specific risk factors. In the UK, NICE advocate 
that women should be started on 75mg of aspirin daily until the birth of the baby if they have 
one high risk factor or two moderate risk factors (See table 1.5). In the United States, ACOG 
recommend taking a medical history to evaluate the woman’s risk of PE. They suggest only 
prescribing aspirin (80mg) to women with a history of PE in two or more previous pregnancies 
or to those who required delivery in a prior pregnancy before 34 weeks’ gestation as a result 
of PE. The approach suggested by these two bodies, effectively treats each risk factor as a 
separate screening test. 
 
This study examined the performance of screening based on risk factors from the medical 
history as recommended by NICE and ACOG against our competing risks model. In 
comparison to our model, the recommended approach by NICE performed significantly lower 
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with a DR of 41% and 39% for PE requiring delivery before 32 and 37 weeks’ gestation, 
respectively, at a FPR of 10.2%. The ACOG approach had high DRs of 94% and 90% for PE 
<32 and <37 weeks’ gestation but with a FPR of 64.2% and based on their recommendation 
for prescribing low dose aspirin, we found their DRs would be 6%, 5%, and 2% for PE requiring 
delivery before 32 and 37 weeks’ gestation and after 37 weeks respectively.  
  
4.4 Implications for clinical practice 
It was first realised that aspirin was associated with a lower risk of PE in high-risk nulliparous 
women in 1979 (Crandon and Isherwood). Another study randomised high risk women to either 
150mg of aspirin and 300mg of dipyridamole or no treatment (Beaufils et al., 1985) and found 
the incidence of PE in the treatment group significantly less compared to the control group. 
Since then, there have been many studies investigating this subject with no definitive 
conclusion. The controversy is a result of the very heterogeneous nature in the methodology 
used in these studies with respect to population, screening method, dose and time of initiation 
of aspirin and definitions of PE (Duley et al., 2006.) Recent meta-analyses have suggested 
that the effect of aspirin in the prevention of PE is gestation-dependent (Bujold et al., 2010) 
and that a 50% reduction in the incidence of PE is achievable if aspirin is commenced before 
16 weeks’ gestation, and particularly the incidence of severe and preterm forms of the disease 
(Roberge et al., 2012a and 2012b). These observations were, however, questioned as in these 
meta-analyses, the number of women given aspirin before 16 weeks’ gestation was small in 
comparison to those whom commenced aspirin after 16 weeks’ gestation and there were no 
major randomised controlled trials confirming such findings. These criticisms were answered 
by two major studies. Park et al. (2015) performed a retrospective cohort analysis of 7,783 
patients showing that a combination of first-trimester PE screening combined with 150 mg of 
aspirin daily in high-risk women reduced the risk of preterm PE by 55% in their population 
(Park et al., 2015). More recently, Rolnik et al. published the results of the ASPRE trial that 
screened 26,941 patients for PE at 11 to 13 weeks’ gestation using the competing risks model 
described in chapter 3 and randomised 1,776 women at high risk of PE. They found a 
significant 62% reduction on preterm PE when aspirin was given at a 150mg dose and initiated 
before 16 weeks’ gestation. Whilst the effect on term PE was minimal, there was an overall 
30% reduction in all forms of disease (Rolnik et al., 2017).  
Historically, the current approach to prenatal care is based on a pyramid of care that involved 
a first visit at 12 weeks’ gestation and a high concentration of visits in the second and, mainly, 
in the third trimester of pregnancy. Since the early 1990’s, however, there has been a shift 
towards attempting to predict pregnancy complications in the first trimester (Nicolaides, 
2011a). Early identification of high-risk women allows appropriate counselling regarding 
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changes in lifestyle (such as healthy diet, exercising, weight gain recommendations) and early 
initiation of other preventive measures (Nicolaides, 2011a). 
In a proposed new pyramid of pregnancy care (Nicolaides, 2011b) an integrated antenatal visit 
at 11+0 to 13+6 weeks’ gestation at the same time as the well-established process of first 
trimester screening for chromosomal abnormalities, can provide a framework for population-
based screening and preventive interventions. This study provides evidence that screening for 
PE using biochemical and biophysical markers combined with maternal factors, can be added 
to this first trimester routine visit. For units wishing to implement this algorithm, the choice of 
which combination of markers used, will depend on the feasibility of its introduction, as well as, 
the healthcare costs. The measurement of the MAP can be easily performed by any member 
of the healthcare team using automated, pregnancy validated, blood pressure machines. A 
strict protocol is required to be followed and a mechanism for careful surveillance of the quality 
of the measurements should be put in place. The uterine artery PI can be performed by the 
same sonographer who carries out the first trimester scan following specific training to ensure 
correct measurements. In many countries, the infrastructure is already in place for the 
measurement of PAPP-A in centres that provide routine first trimester screening for 
aneuploidies. The PlGF measurement can be performed on the same blood sample by the 
same machine as PAPP-A, albeit at an extra cost.    
The findings of the above studies demonstrate that in first-trimester screening for PE the 
performance of the test is better for early rather than late disease. This is particularly relevant 
as the objective of early screening is to identify the high-risk group that may benefit from, the 
now, proven therapeutic interventions, aspirin 150mg initiated before 16 weeks’ gestation, that 
reduce the prevalence of preterm PE.  
4.5 Strengths and Limitations 
These studies included a large population of pregnant women who attended for routine care 
in a gestational age range widely used for the assessment of risk of chromosomal 
abnormalities. The adherence to the strict protocols and appropriately trained personnel was 
a strength of these studies, which contributed to the high quality of data obtained. Another 
strength was the use of automated machines to provide accurate measurements of markers 
within 40 minutes of sampling. Importantly, the biomarkers were expressed in MoMs after 
adjustment for the factors that affect their measurement. This approach adjusted for additional 
factors that influence the biomarkers in the algorithm and consequently the risk calculation. 
The use of Bayes’ theorem to combine the prior risk with biomarkers to estimate patient specific 
risks contributed significantly to the performance of the screening. All patient medical records, 
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with a suspected diagnosis of hypertensive disease in pregnancy and IUGR, where thoroughly 
reviewed to ensure an accurate diagnosis.  
 
A limitation of the competing risks model study is that it was derived and tested with the use of 
the same dataset. One criticism of this approach is that it can lead to an overestimation and 
overfitting. Overfitting occurs when a model corresponds very closely or exactly to a particular 
set of data. It may therefore fail to accommodate at fit additional data or even predict future 
observations reliably. To limit this potential bias, a five-fold cross validation was used. A major 
strength in this study is the prospective validation of this model using a new data set. 
 
The main limitation of the validation and comparison study relates to the low incidence of 
delivery with PE with the inevitable wide confidence intervals obtained for performance of 
screening. However, the values and detection rates obtained from the validation study are very 
similar to those in the dataset of the competing risks model that was used for the development 
of the model. 
 
4.6 Future studies 
First trimester screening for preterm PE performs well and can successfully identify a 
significant proportion of women that will develop this disorder. However, owing to the complex 
nature of this disease, no single predictive marker exists. Identifying potentially superior 
predictive markers is the focus of ongoing research. Additionally, the first trimester prediction 
of term PE is still poor, raising the hypothesis that the mechanism of disease is different in 
these cases (Melchiorre et al. 2011). Early PE is associated with a very high-risk of maternal 
and perinatal morbidity and mortality, and late PE and its consequences have a significant 
impact on public health since this condition is more common. Aspirin significantly reduces the 
incidence of preterm PE but has little or no effect on term disease. This may be due to the poor 
performance of actually detecting term disease or aspirin is converting what would have been 
early PE to late PE. Better methods of prediction and prevention of late PE are needed.  
4.6.1 Proteomics 
Mass spectrometry-based proteomics has been an exciting breakthrough and in theory could 
provide vital information necessary for understanding the mechanisms of complex human 
diseases, such as PE, through the discovery of novel biomarkers. It is an automated technique 
that can detect large numbers of peptides from biological fluids, thus yielding a proteomic 
signature that can be distinguished from matched control cases.  
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A number of previously published studies have verified that proteomics can identify peptides 
specific to preeclampsia (Pecks et al., 2010, Blankly et al., 2013). Myers et al. (2013) externally 
validated their proteomic signature with plasma samples taken at 22 and 26 weeks of 
gestation. They described a prediction model with a DR of 54% and 80% with a 20% positive 
predictive value (PPV) for PE and preterm PE respectively. However, there are very limited 
data available on first trimester screening for PE using proteomics. One study used quantitative 
proteomic (iTRAQ) analysis of maternal plasma samples taken at 12 weeks’ gestation and 
found that there were 31 proteins upregulated and 20 proteins downregulated in patients that 
subsequently developed PE, demonstrating the potential for the development of a first 
trimester screening model for PE using proteomics (Liu et al., 2011). This could provide an 
interesting avenue of exploration that yields biomarkers that could be used alone or combined 
with existing screening risk models. 
4.6.2 Metabolomics 
Metabolites are the intracellular molecules that undergo transformation when metabolised and 
in effect, provide a blueprint log of its cellular biochemistry. Metabolomics is the detection and 
semi-quantitation of low molecular weight metabolites present in cells, tissues or body fluids, 
using proton nuclear magnetic resonance (1H NMR) spectroscopy or mass spectrometry. 
Recently, there has been emerging interest in this approach to predict PE.  First trimester 
prediction of PE using metabolomic markers have been published (Bahado-Singh et al., 2012 
and 2013). They reported such an approach appeared highly predictive of early PE with an 
estimated detection rate of 75.9%, at a false-positive rate (FPR) of 4.9%. This was further 
improved by the addition of uterine artery Doppler PI and fetal crown-rump length (CRL) and 
with an estimated detection rate of 82.6%, at a FPR of 1.6%. Metabolomic prediction for late 
PE did not perform as well. However, a complex mix of potential pathways for disease 
development was identified, which could lead to exciting new therapeutic options in the future. 
This approach affords more than just mere biomarker development. It may also generate 
significant insights into the pathophysiology of this disorder. 
4.6.3 Fetal haemoglobin 
Extracellular fetal haemoglobin (HbF) was first suggested to be implicated in the pathogenesis 
of PE in 2008 by Centlow et al. They found an upregulation of HbF genes and accumulation 
of extracellular HbF in the vascular lumen in PE placentas. HbF has been suggested to be a 
causative factor of PE (Hansson et al., 2013). More recently, HbF and the heme-scavenger 
a1- microglobulin (A1M) were found to be significantly raised in patients with a diagnosis of PE 
(Anderson et al., 2015) raising the possibility of potentially two new biomarkers. Further larger 





Using a competing risks model, an algorithm that incorporated maternal characteristics with 
biophysical and biochemical markers, was developed to screen pregnant women from 11 to 
13 weeks’ gestation for PE. This study, based on 35,948 singleton pregnancies, had a DR of 
75% and 47% for PE requiring delivery before and after 37 weeks’ gestation respectively, at a 
FPR of 10% (O’Gorman et al., 2016).   
 
In our prospective European multicentre validation study, we screened 9,041 women with 
singleton pregnancies. The same protocols were employed at all centres ensuring 
homogeneity of the methodology and quality of the results. This study found similar DR to 
those predicted from the model (DR of PE before and after 37 weeks’ gestation 75% and 43% 
respectively at a FPR of 10%), thus validating the prediction algorithm and illustrating its 
reproducibility at external centres (O’Gorman et al., 2017a). 
 
The same data from the validation study was used to examine the performance of screening 
based on risk factors from the patient’s medical history as recommended by NICE and ACOG. 
In comparison to the DRs from our competing risks model, the screening approach endorsed 
by NICE performed significantly lower for the detection of preterm PE with DRs of 39% and 
34% of PE before and after 37 weeks’ gestation respectively at a FPR of 10%. While our model 
detected 100% of PE requiring delivery before 32 weeks’ gestation, the recommended 
approach by NICE detected just 41% at the same FPR (O’Gorman et al., 2017b).  
 
The DR were higher in the screening approach suggested by ACOG 94%, 90% and 89% for 
PE <32, <37 and >37 weeks’ gestation respectively but had a higher FPR of 64.2%. 
Interestingly, based on their recommendations as to whom aspirin should be given to, ACOG 
would only detect 6%, 5%, and 2% of women developing PE requiring delivery before 32 and 
37 weeks’ gestation and after 37 weeks’ gestation respectively (O’Gorman et al., 2017b).  
 
In conclusion, the studies included in the papers of Chapter 3 demonstrate that effective 
screening for PE at 11 to 13 weeks’ gestation is feasible internationally. We developed a model 
that has a high DR for PE requiring delivery before 37 weeks’ gestation. The algorithm was 
prospectively validated and subsequently proven to perform better than, the screening models 
endorsed by the NICE and the ACOG. This effective screening model is perfectly timed to 
facilitate the initiation of aspirin, which has been proven to significantly decrease the incidence 
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